<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">bXdPznQtSqPZYgQyS9KNrrL</article-id>
      <article-id pub-id-type="other">00012</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2011000200012</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(11)09600212</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2011005000003</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigo de Revis&#227;o</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Comportamento dos quimiorreflexos central e perif&#233;rico na insufici&#234;ncia card&#237;aca</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Guimar&#227;es</surname>
            <given-names>Guilherme Veiga</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Belli</surname>
            <given-names>Juliana Fernanda Canhadas</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bacal</surname>
            <given-names>Fernando</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bocchi</surname>
            <given-names>Edimar Alcides</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff02">
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade de S&#227;o Paulo</institution>
        <institution content-type="orgdiv1">Centro de Pr&#225;ticas Esportivas </institution>
        <institution content-type="orgdiv2">Laborat&#243;rio de Atividade F&#237;sica e Sa&#250;de</institution>
        <country country="BR">Brazil</country>
      </aff>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade de S&#227;o Paulo</institution>
        <institution content-type="orgdiv1">Faculdade de Medicina </institution>
        <institution content-type="orgdiv2">Hospital das Cl&#237;nicas</institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>02</month>
        <year>2011</year>
      </pub-date>
      <volume>96</volume>
      <issue>2</issue>
      <fpage>161</fpage>
      <lpage>167</lpage>
      <history>
        <date date-type="accepted">
          <day>07</day>
          <month>10</month>
          <year>2009</year>
        </date>
        <date date-type="rev-recd">
          <day>20</day>
          <month>08</month>
          <year>2009</year>
        </date>
        <date date-type="received">
          <day>23</day>
          <month>06</month>
          <year>2009</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>A s&#237;ndrome da insufici&#234;ncia card&#237;aca (IC) pode ser definida como via final de qualquer forma de doen&#231;a card&#237;aca. Os reflexos cardiovasculares simpatoinibit&#243;rios como o reflexo arterial barorreceptor est&#227;o significativamente suprimidos na IC. Pacientes com IC apresentam maior ventila&#231;&#227;o para determinada carga de trabalho quando comparados a indiv&#237;duos normais. Esse fato gera baixa efici&#234;ncia ventilat&#243;ria e relaciona-se com maior ventila&#231;&#227;o relativa &#224; produ&#231;&#227;o de g&#225;s carb&#244;nico, que &#233; um preditor de mau progn&#243;stico, al&#233;m de ser um fator limitante ao exerc&#237;cio. H&#225; evid&#234;ncias de que o desequil&#237;brio auton&#244;mico contribua para a patog&#234;nese e a progress&#227;o da insufici&#234;ncia card&#237;aca. Os quimiorreflexos s&#227;o os principais mecanismos de controle e regula&#231;&#227;o das respostas ventilat&#243;rias &#224;s mudan&#231;as de concentra&#231;&#227;o do oxig&#234;nio e g&#225;s carb&#244;nico arterial. A ativa&#231;&#227;o do quimiorreflexo causa aumento da atividade simp&#225;tica, frequ&#234;ncia card&#237;aca, press&#227;o arterial e volume minuto. No entanto, o aumento do volume minuto e da press&#227;o arterial, pelo feedback negativo provocam inibi&#231;&#227;o da resposta simp&#225;tica &#224; ativa&#231;&#227;o do quimiorreflexo. Apesar das altera&#231;&#245;es funcionais dos reflexos, seu comportamento em condi&#231;&#245;es normais e patol&#243;gicas, especialmente sua contribui&#231;&#227;o para o estado simpatoexcitat&#243;rio encontrado na IC, n&#227;o tem sido amplamente estudado. Dessa forma, esta revis&#227;o tem por objetivo integrar os conhecimentos a respeito dos quimiorreflexos central e perif&#233;rico na s&#237;ndrome da insufici&#234;ncia card&#237;aca, bem como esclarecer a influ&#234;ncia da terap&#234;utica medicamentosa da insufici&#234;ncia card&#237;aca nos quimiorreflexos.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Insufici&#234;ncia card&#237;aca</kwd>
        <kwd>sistema nervoso aut&#244;nomo</kwd>
        <kwd>barorreflexo</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>07</day>
        <month>01</month>
        <year>2011</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>Comportamento dos quimiorreflexos central e perif&#233;rico na insufici&#234;ncia card&#237;aca</p>
    <p>
      <bold>Guilherme Veiga Guimar&#227;es<sup>I,II</sup>; Juliana Fernanda Canhadas Belli<sup>I,II</sup>; Fernando Bacal<sup>I</sup>; Edimar Alcides Bocchi<sup>I</sup></bold>
    </p>
    <p><sup>I</sup>Instituto do Cora&#231;&#227;o do Hospital das Cl&#237;nicas da Faculdade de Medicina da Universidade de S&#227;o Paulo </p>
    <p><sup>II</sup>Laborat&#243;rio de Atividade F&#237;sica e Sa&#250;de do Centro de Pr&#225;ticas Esportivas da Universidade de S&#227;o Paulo, S&#227;o Paulo, SP - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="nt">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p>A s&#237;ndrome da insufici&#234;ncia card&#237;aca (IC) pode ser definida como via final de qualquer forma de doen&#231;a card&#237;aca. Os reflexos cardiovasculares simpatoinibit&#243;rios como o reflexo arterial barorreceptor est&#227;o significativamente suprimidos na IC. Pacientes com IC apresentam maior ventila&#231;&#227;o para determinada carga de trabalho quando comparados a indiv&#237;duos normais. Esse fato gera baixa efici&#234;ncia ventilat&#243;ria e relaciona-se com maior ventila&#231;&#227;o relativa &#224; produ&#231;&#227;o de g&#225;s carb&#244;nico, que &#233; um preditor de mau progn&#243;stico, al&#233;m de ser um fator limitante ao exerc&#237;cio. H&#225; evid&#234;ncias de que o desequil&#237;brio auton&#244;mico contribua para a patog&#234;nese e a progress&#227;o da insufici&#234;ncia card&#237;aca. Os quimiorreflexos s&#227;o os principais mecanismos de controle e regula&#231;&#227;o das respostas ventilat&#243;rias &#224;s mudan&#231;as de concentra&#231;&#227;o do oxig&#234;nio e g&#225;s carb&#244;nico arterial. A ativa&#231;&#227;o do quimiorreflexo causa aumento da atividade simp&#225;tica, frequ&#234;ncia card&#237;aca, press&#227;o arterial e volume minuto. No entanto, o aumento do volume minuto e da press&#227;o arterial, pelo <italic>feedback</italic> negativo provocam inibi&#231;&#227;o da resposta simp&#225;tica &#224; ativa&#231;&#227;o do quimiorreflexo. Apesar das altera&#231;&#245;es funcionais dos reflexos, seu comportamento em condi&#231;&#245;es normais e patol&#243;gicas, especialmente sua contribui&#231;&#227;o para o estado simpatoexcitat&#243;rio encontrado na IC, n&#227;o tem sido amplamente estudado. Dessa forma, esta revis&#227;o tem por objetivo integrar os conhecimentos a respeito dos quimiorreflexos central e perif&#233;rico na s&#237;ndrome da insufici&#234;ncia card&#237;aca, bem como esclarecer a influ&#234;ncia da terap&#234;utica medicamentosa da insufici&#234;ncia card&#237;aca nos quimiorreflexos.</p>
    <p><bold>Palavras-chave: </bold>Insufici&#234;ncia card&#237;aca/terapia, sistema nervoso aut&#244;nomo, barorreflexo/efeitos de drogas.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>A s&#237;ndrome da insufici&#234;ncia card&#237;aca (IC) pode ser definida como a via final de qualquer forma de doen&#231;a card&#237;aca<sup>1</sup>, na qual desordens estrutural, funcional e neuro-humoral do cora&#231;&#227;o levam &#224; diminui&#231;&#227;o da capacidade do ventr&#237;culo de ejetar e/ou de se encher de sangue nas press&#245;es de enchimento fisiol&#243;gicas<sup>1,2</sup>. Essas altera&#231;&#245;es resultam em disfun&#231;&#227;o card&#237;aca sist&#243;lica, diast&#243;lica ou ambas e, consequentemente, perda da capacidade funcional, diminui&#231;&#227;o da qualidade de vida e aumento da morbidade e mortalidade<sup>3,4</sup>. </p>
    <p>A s&#237;ndrome de insufici&#234;ncia card&#237;aca associa-se a dist&#250;rbios hemodin&#226;micos seguidos de altera&#231;&#245;es sist&#234;micas, disfun&#231;&#227;o endotelial, ativa&#231;&#227;o neuro-hormonal, com aumento na libera&#231;&#227;o de catecolaminas, maiores n&#237;veis de pept&#237;deo natriur&#233;tico cerebral (BNP-B)<sup>5</sup> e libera&#231;&#227;o de fatores pr&#243;-inflamat&#243;rios que contribuem para a dilata&#231;&#227;o card&#237;aca e menor desempenho frente ao exerc&#237;cio f&#237;sico<sup>5,6</sup>. Pacientes com IC apresentam maior ventila&#231;&#227;o para determinada carga de trabalho quando comparados a indiv&#237;duos normais<sup>7</sup>. Esse fato gera baixa efici&#234;ncia ventilat&#243;ria e relaciona-se com maior ventila&#231;&#227;o relativa &#224; produ&#231;&#227;o de g&#225;s carb&#244;nico que &#233; um importante preditor de mau progn&#243;stico, al&#233;m de ser um fator limitante ao exerc&#237;cio<sup>8,9</sup>.</p>
    <p>A hiperventila&#231;&#227;o pode ocorrer por diversas causas, dentre elas a hiperatividade dos reflexos advindos de quimiorreceptores, uma das diversas anormalidades no controle reflexo cardiovascular relacionado ao t&#244;nus simp&#225;tico aumentado na IC<sup>7,10</sup>. A hiperativa&#231;&#227;o dos sinais originados dos receptores localizados nos m&#250;sculos esquel&#233;ticos (mecnocrreceptores - metaborreceptores) &#233; uma hip&#243;tese proposta recentemente para explicar a origem dos sintomas de intoler&#226;ncia ao esfor&#231;o f&#237;sico<sup>6</sup></p>
    <p>Os reflexos cardiovasculares simpatoinibit&#243;rios como o reflexo arterial barorreceptor est&#227;o significativamente suprimidos na IC. Por sua vez, os reflexos simpatoexcitat&#243;rios, incluindo o reflexo dos quimiorreceptores arteriais e os reflexos card&#237;acos simp&#225;tico-aferentes, est&#227;o aumentados na IC. Apesar das altera&#231;&#245;es funcionais dos reflexos terem sido usadas de maneira independente para ilustrar a excita&#231;&#227;o simp&#225;tica observada na IC, a intera&#231;&#227;o entre esses reflexos em condi&#231;&#245;es normais e patol&#243;gicas, especialmente sua contribui&#231;&#227;o para o estado simpatoexcitat&#243;rio encontrado na IC, n&#227;o tem sido amplamente estudados<sup>11</sup>. Assim, o objetivo deste artigo &#233; fazer uma revis&#227;o a respeito do mecanismo de a&#231;&#227;o dos quimiorreflexos perif&#233;rico e central.</p>
    <p>
      <bold>Regula&#231;&#227;o cardiopulmonar</bold>
    </p>
    <p>Os receptores cardiopulmonares localizam-se, basicamente, em associa&#231;&#227;o com os grandes vasos arteriais do t&#243;rax e do pesco&#231;o e transmitem est&#237;mulos para o centro respirat&#243;rio, para ajudar a regular a atividade respirat&#243;ria. A maioria deles se encontra nos corp&#250;sculos a&#243;rticos e carot&#237;deos, ao longo de suas conex&#245;es nervosas aferentes com o centro respirat&#243;rio. Os corp&#250;sculos carot&#237;deos se localizam bilateralmente nas bifurca&#231;&#245;es das art&#233;rias car&#243;tidas principais e suas fibras aferentes passam atrav&#233;s dos nervos de Hering para os nervos glossofar&#237;ngeos e da&#237; ao bulbo. Os corp&#250;sculos a&#243;rticos se localizam ao longo da cro&#231;a da aorta e suas fibras nervosas passam para o bulbo atrav&#233;s do nervo vago e para a medula espinhal via nervos simp&#225;ticos<sup>12</sup> (<xref ref-type="fig" rid="fig01">fig. 1</xref>). Tr&#234;s conjuntos de receptores cardiopulmonares podem ser identificados: 1) aferentes card&#237;acos vagais n&#227;o mielinizados, que s&#227;o pequenas termina&#231;&#245;es nervosas espalhadas nas c&#226;maras card&#237;acas, sens&#237;veis &#224; distens&#227;o mec&#226;nica por altera&#231;&#245;es na press&#227;o atrial ou na press&#227;o diast&#243;lica final, e por provocarem repostas semelhantes aos barorreceptores arteriais sup&#245;e-se que ambos utilizem as mesmas vias neuronais; 2) aferentes card&#237;acos vagais mielinizados, localizados especialmente na jun&#231;&#227;o das grandes veias e &#225;trios, espontaneamente ativos durante a s&#237;stole e a di&#225;stole, e que fornecem informa&#231;&#245;es ao sistema nervoso central sobre o grau de enchimento atrial e a frequ&#234;ncia card&#237;aca. Em situa&#231;&#245;es de aumento da volemia, provocam redu&#231;&#227;o na atividade nervosa simp&#225;tica renal e, consequentemente, diminui&#231;&#227;o na libera&#231;&#227;o de vasopressina pela neuro-hip&#243;fise. Nessa condi&#231;&#227;o, ocorre tamb&#233;m aumento nos n&#237;veis de pept&#237;deo natriur&#233;tico atrial, o que induz a eleva&#231;&#245;es na diurese e na natriurese, al&#233;m de inibi&#231;&#227;o da libera&#231;&#227;o de renina e aldosterona; e 3) aferentes espinhais que trafegam junto com o simp&#225;tico e est&#227;o distribu&#237;dos ao longo das art&#233;rias coron&#225;rias, das c&#226;maras card&#237;acas e dos grandes vasos tor&#225;cicos. Assim, suas fibras aferentes caminham junto aos nervos card&#237;acos simp&#225;ticos at&#233; a medula espinhal e seus corpos celulares est&#227;o presentes nos g&#226;nglios da raiz dorsal. Embora sejam ativados por est&#237;mulos mec&#226;nicos, como quedas na press&#227;o de perfus&#227;o das coron&#225;rias, induzindo vasodilata&#231;&#227;o em situa&#231;&#245;es isqu&#234;micas, e por subst&#226;ncias qu&#237;micas que atuam diretamente no epic&#225;rdio, tais como bradicinina, &#225;cidos org&#226;nicos e cloreto de pot&#225;ssio, exercem um papel protetor importante na sinaliza&#231;&#227;o de sensa&#231;&#245;es dolorosas, como nas de crises de angina<sup>5</sup>. Na IC, o controle reflexo cardiopulmonar est&#225; sensivelmente alterado em raz&#227;o de a resposta nervosa simp&#225;tica reflexa desencadeada pelo enchimento card&#237;aco estar significativamente diminu&#237;da nesses pacientes<sup>13,14</sup>.</p>
    <fig id="fig01">
      <graphic xlink:href="1678-4170-abc-96-02-0161-00003-gf01.jpg"/></fig>
    <p>
      <bold>Controle quimiorreflexo</bold>
    </p>
    <p>O sistema nervoso aut&#244;nomo permite ao organismo ajustar sua circula&#231;&#227;o e ventila&#231;&#227;o para manter o aporte de oxig&#234;nio para os tecidos. O equil&#237;brio auton&#244;mico &#233; mantido pela complexa intera&#231;&#227;o do barorreflexo arterial, quimiorreflexo central e perif&#233;rico, ergorreflexo e reflexo de estiramento pulmonar (<xref ref-type="fig" rid="fig02">fig. 2</xref>). H&#225; evid&#234;ncias de que o desequil&#237;brio auton&#244;mico contribua para a patog&#234;nese e progress&#227;o da insufici&#234;ncia card&#237;aca<sup>15</sup>.</p>
    <fig id="fig02">
      <graphic xlink:href="1678-4170-abc-96-02-0161-00003-gf02.jpg"/></fig>
    <p>Os quimiorreflexos s&#227;o os principais mecanismos de controle e regula&#231;&#227;o das respostas ventilat&#243;rias &#224;s mudan&#231;as de concentra&#231;&#227;o do oxig&#234;nio e g&#225;s carb&#244;nico arterial<sup>16</sup>. Os quimiorreceptores perif&#233;ricos localizados nos corpos carot&#237;deos e a&#243;rtico, com afer&#234;ncias para o centro respirat&#243;rio no bulbo e para o n&#250;cleo do trato solit&#225;rio, respondem primariamente &#224; hip&#243;xia<sup>16,17</sup>. Os quimiorreceptores centrais, localizados na superf&#237;cie ventral da medula espinhal, respondem primariamente &#224; hipercapnia<sup>18</sup>. Ambas as respostas &#224;s altera&#231;&#245;es da concentra&#231;&#227;o de O<sub>2</sub> e CO<sub>2</sub> respectivamente, aumentam a ventila&#231;&#227;o pulmonar. Quase simultaneamente, outro conjunto de neur&#244;nios que chega ao n&#250;cleo do trato solit&#225;rio induz aumento na atividade nervosa simp&#225;tica. Ambos os mecanismos quimiorreceptores exercem grande influ&#234;ncia no controle neural da circula&#231;&#227;o, especialmente em situa&#231;&#245;es envolvendo mudan&#231;as marcantes na concentra&#231;&#227;o arterial de oxig&#234;nio e/ou CO<sub>2</sub>. A ativa&#231;&#227;o do quimiorreflexo causa aumento da atividade simp&#225;tica, frequ&#234;ncia card&#237;aca, press&#227;o arterial e volume minuto. No entanto, o aumento do volume minuto e da press&#227;o arterial, pelo <italic>feedback</italic> negativo, provoca inibi&#231;&#227;o da resposta simp&#225;tica &#224; ativa&#231;&#227;o do quimiorreflexo. Dessa forma, quimiorreflexos desencadeiam diversas respostas cardiovasculares e respirat&#243;rias, com intera&#231;&#245;es complexas entre suas respostas. Para definir qualquer anormalidade na fun&#231;&#227;o quimiorreflexa &#233; essencial considerar a contribui&#231;&#227;o individual de cada componente que integra essa resposta. Em pacientes com IC, a estimula&#231;&#227;o dos quimiorreceptores centrais e perif&#233;ricos provoca aumento exagerado na ventila&#231;&#227;o pulmonar e na atividade nervosa simp&#225;tica caracterizada por uma potencializa&#231;&#227;o seletiva dessas respostas<sup>14,19</sup>.</p>
    <p>
      <bold>Contribui&#231;&#227;o dos quimiorreflexos sob condi&#231;&#245;es de norm&#243;xia</bold>
    </p>
    <p>Os quimiorreflexos (centrais e perif&#233;ricos) exercem um papel essencial no controle da ventila&#231;&#227;o alveolar para garantir que as taxas de troca gasosa nos pulm&#245;es continuamente supram a demanda metab&#243;lica pela capta&#231;&#227;o de oxig&#234;nio e remo&#231;&#227;o de CO<sub>2</sub>. Frequentemente superestimado, entretanto, &#233; o fato de que esses reflexos tamb&#233;m exercem importantes influ&#234;ncias no controle card&#237;aco e vascular para regular o fluxo sangu&#237;neo e ent&#227;o os n&#237;veis teciduais de troca gasosa. Um componente importante para ativa&#231;&#227;o do quimiorreflexo &#233; um aumento na atividade simp&#225;tica nos leitos vasculares. Essa resposta ajuda na manuten&#231;&#227;o da press&#227;o arterial em face dos efeitos diretos vasodilatadores da hipoxemia ou hipercapnia, e ent&#227;o auxilia na manuten&#231;&#227;o da press&#227;o adequada para o fluxo sangu&#237;neo e troca gasosa nos tecidos. </p>
    <p>A ideia de que os quimiorreflexos contribuem para a atividade simp&#225;tica de repouso em estados patol&#243;gicos tem sido a hip&#243;tese que os quimiorreflexos n&#227;o estariam ativados no repouso (norm&#243;xia e isocapnia) e ent&#227;o deveriam ter pequena influ&#234;ncia no t&#244;nus simp&#225;tico sob condi&#231;&#245;es normais. No entanto, essa hip&#243;tese mostra-se controversa. Em indiv&#237;duos normais em repouso, a hiper&#243;xia, que inibe a atividade de quimiorreceptores perif&#233;ricos, diminui a atividade nervosa simp&#225;tica<sup>20</sup>. Entretanto, indiv&#237;duos com apneia do sono t&#234;m uma atividade quimiorreflexa aumentada em condi&#231;&#245;es de norm&#243;xia. Assim, pode-se sugerir que os quimiorreflexos contribuem para o t&#244;nus simp&#225;tico aumentado na insufici&#234;ncia card&#237;aca, mesmo na aus&#234;ncia de hip&#243;xia<sup>21</sup>.</p>
    <p>
      <bold>Quimiorreflexos e anormalidades ventilat&#243;rias </bold>
    </p>
    <p>A respira&#231;&#227;o &#233; estimulada pelos quimiorreflexos que incluem os receptores centrais e perif&#233;ricos, o sistema nervosos central e os m&#250;sculos respirat&#243;rios. Os quimiorreflexos comp&#245;em a parte de <italic>feedback</italic> negativo de um ciclo de retroalimenta&#231;&#227;o. O ciclo &#233; completado pela progress&#227;o na qual a ventila&#231;&#227;o alveolar controla a extra&#231;&#227;o de O<sub>2</sub> e elimina&#231;&#227;o de CO<sub>2</sub>. A progress&#227;o do ciclo relaciona a depend&#234;ncia da PCO<sub>2</sub> e da PO<sub>2</sub> na ventila&#231;&#227;o<sup>22</sup>. A estimula&#231;&#227;o dos quimiorreceptores resulta em uma ventila&#231;&#227;o alveolar aumentada que leva a uma elimina&#231;&#227;o aumentada de CO<sub>2</sub> e queda na PCO<sub>2</sub>, estimulando os quimiorreceptores por meio do aumento da concentra&#231;&#227;o de &#237;ons H<sup>+</sup>; dessa forma, concluindo a designa&#231;&#227;o de retroalimenta&#231;&#227;o negativa do sistema<sup>23</sup> (<xref ref-type="fig" rid="fig03">fig. 3</xref>). </p>
    <fig id="fig03">
      <graphic xlink:href="1678-4170-abc-96-02-0161-00003-gf03.jpg"/></fig>
    <p>A sensibilidade aumentada dos quimiorreflexos central e perif&#233;rico pode exercer um importante papel no controle ventilat&#243;rio alterado na insufici&#234;ncia card&#237;aca, sendo encontrada correla&#231;&#227;o significativa entre a resposta ventilat&#243;ria ao exerc&#237;cio e a quimiossensibilidade hipox&#234;mica ao repouso<sup>24</sup>. A inibi&#231;&#227;o do quimiorreflexo perif&#233;rico tem mostrado aumentar o desempenho ante o exerc&#237;cio e diminuir a resposta ventilat&#243;ria em pacientes com IC. Essas observa&#231;&#245;es sugerem que a hiperpneia exacerbada ante o exerc&#237;cio pode ser influenciada pelo aumento da atividade quimiorreflexa perif&#233;rica nesses pacientes<sup>25,26</sup>. Uma correla&#231;&#227;o positiva significativa foi encontrada entra a responsividade central ventilat&#243;ria hiperc&#225;pnica e a porcentagem do tempo de sono em pacientes com IC e respira&#231;&#227;o de Cheyne-Stokes. O fato de O<sub>2 </sub>e CO<sub>2</sub> suplementares durante o sono aumentarem a respira&#231;&#227;o de Cheyne-Stokes sugere uma contribui&#231;&#227;o da quimiossensibilidade aumentada nessa desordem. Esse aumento tamb&#233;m pode explicar a tend&#234;ncia de PaCO<sub>2 </sub>menores do que o normal ser observada durante o sono e a vig&#237;lia nos indiv&#237;duos com respira&#231;&#227;o de Cheyne-Stokes<sup>26</sup>.</p>
    <p>Na insufici&#234;ncia card&#237;aca de etiologia chag&#225;sica as respostas ventilat&#243;ria e auton&#244;mica foram aumentadas com a estimula&#231;&#227;o do quimiorreflexo perif&#233;rico. Em contrapartida, as respostas ventilat&#243;ria e auton&#244;mica diminu&#237;ram durante a hipercapnia, associada &#224; ativa&#231;&#227;o dos quimiorreceptores centrais nesse grupo de pacientes<sup>27,28</sup>.</p>
    <p>Al&#233;m disso, &#233; importante ressaltar que ao lado da doen&#231;a de Chagas, o diabete &#233; uma doen&#231;a que pode cursar com neuropatia auton&#244;mica levando &#224; disautonomia e muitas vezes pacientes com IC apresentam o diabete como comorbidade. Existem poucos estudos que relacionam o diabete e a fun&#231;&#227;o quimiorreflexa. Em modelos experimentais, estudos mostram que o quimiorreflexo encontra-se diminu&#237;do<sup>29</sup>. J&#225; em humanos, observa-se diminui&#231;&#227;o do quimiorreflexo perif&#233;rico em indiv&#237;duos com diabete tipo 2, especialmente em rela&#231;&#227;o &#224; resposta a hip&#243;xia<sup>30</sup>.</p>
    <p>
      <bold>Influ&#234;ncia da terap&#234;utica medicamentosa nos quimiorreflexos central e perif&#233;rico</bold>
    </p>
    <p>A terap&#234;utica medicamentosa &#233; fundamental para melhor progn&#243;stico na IC. O tratamento contempor&#226;neo da IC inclui betabloqueadores (BB), inibidores da enzima da convers&#227;o da angiotensina (I-ECA) e bloqueadores do receptor da angiotensina II (BRA). A terap&#234;utica com betabloqueadores modificou de forma importante a morbidade e mortalidade dos doentes com IC, como foi evidenciado nos estudos COPERNICUS<sup>31</sup>, CIBIS-II<sup>32</sup> e MERIT-HF<sup>33</sup>. Os betabloqueadores diminuem a progress&#227;o da disfun&#231;&#227;o ventricular esquerda, diminuem atividade simp&#225;tica e assim melhoram o progn&#243;stico dos pacientes com IC<sup>34</sup>. Seus efeitos ben&#233;ficos s&#227;o evidentes independentemente da idade ou do risco baixo, intermedi&#225;rio ou alto que os pacientes se encontram para IC<sup>35</sup>. Entretanto isso n&#227;o se traduz em melhora da capacidade de exerc&#237;cio tanto em esfor&#231;o subm&#225;ximo quanto m&#225;ximo.</p>
    <p>Os betabloqueadores podem atuar nos receptores beta 1 e/ou beta 2 adren&#233;rgicos. O sistema respirat&#243;rio &#233; caracterizado por preval&#234;ncia de receptores beta 2 que s&#227;o caracterizados por regular o t&#244;nus br&#244;nquico enquanto os receptores beta alveolares regulam a reabsor&#231;&#227;o de fluidos que afeta a difus&#227;o dos gases; entretanto, mais de 90% dos receptores beta localizam-se nos alv&#233;olos, nos quais o tipo beta 2 predomina (70%)<sup>36,37</sup>. Apesar de a terap&#234;utica com betabloqueadores ser um tratamento efetivo para a IC, at&#233; o presente momento, apenas alguns estudos avaliaram os efeitos de betabloqueadores na hiperventila&#231;&#227;o induzida pelo exerc&#237;cio<sup>38</sup>. Al&#233;m disso, n&#227;o existem dados a respeito do efeito dos betabloqueadores durante o exerc&#237;cio sob condi&#231;&#245;es de hip&#243;xia, quando a hipoxemia arterial aumenta a atividade dos quimiorreceptores<sup>39</sup>.</p>
    <p>Os inibidores da enzima conversora da angiotensina (IECA) inibem a conves&#227;o de angiotensina I (AI) em angiotensina II (AII), diminuindo os n&#237;veis dessa no sangue. A forma&#231;&#227;o da AII envolve uma clivagem sequencial do angiotensinog&#234;nio. Pela a&#231;&#227;o da renina, sintetizada pelo rim, o angiotensinog&#234;nio &#233; desdobrado em angiotensina I, que &#233; ent&#227;o hidrolizado em angiotensina II, pela a&#231;&#227;o da enzima de convers&#227;o da angiotensina (ECA). O sistema renina-angiotensina-aldosterona pode ser bloqueado em diferentes locais e por mecanismos diversos. A atividade da enzima de convers&#227;o de angiotensina &#233; predominantemente encontrada no endot&#233;lio dos vasos dos pulm&#245;es. A angiotensina II promove libera&#231;&#227;o de aldosterona pela suprarrenal. Os agentes que inibem a ECA interferem na convers&#227;o da AI em AII, essa considerada um dos mais importantes horm&#244;nios sist&#234;micos, entre os quais incluem noradrenalina, vasopressina e endotelina. </p>
    <p>J&#225; os bloqueadores dos receptores da angiotensina II (BRA) s&#227;o f&#225;rmacos que atuam nos receptores AT1, respons&#225;veis por todas as a&#231;&#245;es conhecidas da AII, incluindo vasoconstric&#231;&#227;o, libera&#231;&#227;o de aldosterona e efeitos no mioc&#225;rdio e na vasculatura (<xref ref-type="fig" rid="fig04">fig. 4</xref>). Existem hip&#243;teses para explicar sua influ&#234;ncia na din&#226;mica dos quimiorreflexos central e perif&#233;ricos. Apesar de os mecanismos celulares e moleculares envolvidos no aumento da sensibilidade dos quimiorreceptores carot&#237;deos durante a IC ainda estarem pouco elucidados, existem evid&#234;ncias de que o aumento da concentra&#231;&#227;o da angiotensina II no sistema nervoso central acentua a sensibilidade quimiorreflexa perif&#233;rica e aumenta a atividade nervosa simp&#225;tica perif&#233;rica.</p>
    <p content-type="asset">
      <fig id="fig04">
        <graphic xlink:href="1678-4170-abc-96-02-0161-00003-gf04.jpg"/></fig>
    </p>
    <p>Os n&#237;veis plasm&#225;ticos e teciduais de angiotensina II est&#227;o aumentados na IC e, al&#233;m disso, alguns estudos relacionam a hipersensibilidade dos quimiorreceptores na IC ao aumento nas concentra&#231;&#245;es de AII e &#224; diminui&#231;&#227;o nas concentra&#231;&#245;es de &#243;xido n&#237;trico<sup>42,43</sup>. Estudos recentes demonstraram que concentra&#231;&#227;o end&#243;gena de AII e a express&#227;o dos receptores AT1 est&#227;o aumentados nos corp&#250;sculos carot&#237;deos em modelos animais de IC, e que isso medeia o aumento da sensibilidade dos quimiorreceptores &#224; hip&#243;xia. Dessa forma, o tratamento medicamentoso com BRA poderia afetar os quimiorreflexos na IC, mas os estudos s&#227;o, em sua maioria, experimentais em modelos animais, o que limita a conclus&#227;o do comportamento desses mecanismos em humanos<sup>41,44</sup>.</p>
    <p>
      <bold>Perspectivas</bold>
    </p>
    <p>Apesar de resultados divergentes, atualmente grande n&#250;mero de evid&#234;ncias aponta para que haja um aumento na atividade dos quimiorreflexos centrais e perif&#233;ricos na insufici&#234;ncia card&#237;aca, o que se correlaciona com a gravidade da doen&#231;a. Apesar de os mecanismos respons&#225;veis pela sensibilidade quimiorreflexa central alterada ainda serem obscuros, as altera&#231;&#245;es resultantes podem ser respons&#225;veis, em parte, pelo aumento da resposta ventilat&#243;ria ante exerc&#237;cio, dispneia, respira&#231;&#227;o de Cheyne-Stokes e hiperativa&#231;&#227;o simp&#225;tica observados na insufici&#234;ncia card&#237;aca. Os f&#225;rmacos utilizados no manejo cl&#237;nico da insufici&#234;ncia card&#237;aca, apesar de diminu&#237;rem hiperestimula&#231;&#227;o simp&#225;tica e a sensibilidade dos quimiorreflexos central e perif&#233;rico, n&#227;o melhoram o desempenho ante o exerc&#237;cio, mesmo amenizando sintomas como a dispneia. Dessa forma, a g&#234;nese dos sinais e sintomas da s&#237;ndrome da insufici&#234;ncia card&#237;aca requer maiores esclarecimentos para que se possa intervir e tratar essa s&#237;ndrome de modo a melhorar progn&#243;stico, qualidade de vida e desempenho ante atividades cotidianas.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
    <p>
      <fn id="nt" fn-type="corresp">
        <p>Correspond&#234;ncia:</p>
        <p>Guilherme Veiga Guimar&#227;es </p>
        <p> Rua Dr. Baeta Neves, 98 - Pinheiros </p>
        <p> 05444-050 - S&#227;o Paulo, SP - Brasil </p>
        <p> E-mail: </p>
        <p>
          <email xlink:href="gvguima@usp.br">gvguima@usp.br</email>
        </p>
      </fn>
    </p>
    <p> Artigo recebido em 23/06/09; revisado recebido em 20/08/09; aceito em 07/10/09.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult. American College of Cardiology / American Heart Association. Task Force on Practice Guidelines Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure: developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005; 112 (12): e154-235.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult: American College of Cardiology / American Heart Association. Task Force on Practice Guidelines Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure: developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society</article-title>
          <source>Circulation</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>e154</fpage>
          <lpage>235</lpage>
          <issue>12</issue>
          <volume>112</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hunt</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Abraham</surname>
              <given-names>WT</given-names>
            </name>
            <name>
              <surname>Chin</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Francis</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Ganiats</surname>
              <given-names>TG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Felker GM, Adams KF Jr, Konstam MA, O'Connor CM, Gheorghiade M. The problem of decompensated heart failure: nomenclature, classification, and risk stratification. Am Heart J. 2003;145 (Suppl 2):18-25.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The problem of decompensated heart failure: nomenclature, classification, and risk stratification</article-title>
          <source>Am Heart J</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>18</fpage>
          <lpage>25</lpage>
          <volume>145</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Felker</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Adams Jr</surname>
              <given-names>KF</given-names>
            </name>
            <name>
              <surname>Konstam</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>O'Connor</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Gheorghiade</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Jessup M, Brozena S. Heart failure. N Engl J Med. 2003; 348 (20): 2007-18.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Heart failure</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>2007</fpage>
          <lpage>18</lpage>
          <issue>20</issue>
          <volume>348</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Jessup</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Brozena</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Ramos RB, Fabri J Jr, Mansur AP. A insufici&#234;ncia card&#237;aca no Brasil e no mundo e avalia&#231;&#227;o de sua influ&#234;ncia socioecon&#244;mica. In: Nobre F, Serrano Jr CV. Tratado de cardiologia SOCESP. S&#227;o Paulo: Manole; 2005.</mixed-citation>
        <element-citation publication-type="book">
          <source>Tratado de cardiologia SOCESP</source>
          <date>
            <year>2005</year>
          </date>
          <person-group person-group-type="author">
            <name>
              <surname>Ramos</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Fabri Jr</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Mansur</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Nobre</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Serrano Jr</surname>
              <given-names>CV</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Guimar&#227;es JI, Mesquita ET, Bocchi EA, Vilas-Boas F, Montera MW, Moreira MCV, et al. Revis&#227;o das II Diretrizes da Sociedade Brasileira de Cardiologia para o diagn&#243;stico e tratamento da insufici&#234;ncia card&#237;aca. Arq Bras Cardiol. 2002; 79 (supl. 4): 1-30.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Revis&#227;o das II Diretrizes da Sociedade Brasileira de Cardiologia para o diagn&#243;stico e tratamento da insufici&#234;ncia card&#237;aca</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>1</fpage>
          <lpage>30</lpage>
          <volume>79</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Guimar&#227;es</surname>
              <given-names>JI</given-names>
            </name>
            <name>
              <surname>Mesquita</surname>
              <given-names>ET</given-names>
            </name>
            <name>
              <surname>Bocchi</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Vilas-Boas</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Montera</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Moreira</surname>
              <given-names>MCV</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Piepoli MF, Dimopoulos K, Concu A Crisafulli A. Cardiovascular and ventilatory control during exercise in chronic heart failure: role of muscle reflexes. Int J Cardiol. 2008; 130 (1): 3-10.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiovascular and ventilatory control during exercise in chronic heart failure: role of muscle reflexes</article-title>
          <source>Int J Cardiol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>3</fpage>
          <lpage>10</lpage>
          <issue>1</issue>
          <volume>130</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Piepoli</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Dimopoulos</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Agostoni P, Contini M, Magini A, Apostolo A, Cattadori G, Bussotti M, et al. Carvedilol reduces exercise-induced hyperventilation: a benefit in normoxia and a problem with hypoxia. Eur J Heart Fail. 2006; 8 (7): 729-35.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Carvedilol reduces exercise-induced hyperventilation: a benefit in normoxia and a problem with hypoxia</article-title>
          <source>Eur J Heart Fail</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>729</fpage>
          <lpage>35</lpage>
          <issue>7</issue>
          <volume>8</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Agostoni</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Contini</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Magini</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Apostolo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cattadori</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bussotti</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Kleber FX, Vietzke G, Wernecke KD, Bauer U, Opitz C, Wensel R, et al. Impairment of ventilatory efficiency in heart failure: prognostic impact. Circulation. 2000; 101 (24): 2803-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Impairment of ventilatory efficiency in heart failure: prognostic impact</article-title>
          <source>Circulation</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>2803</fpage>
          <lpage>9</lpage>
          <issue>24</issue>
          <volume>101</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kleber</surname>
              <given-names>FX</given-names>
            </name>
            <name>
              <surname>Vietzke</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Wernecke</surname>
              <given-names>KD</given-names>
            </name>
            <name>
              <surname>Bauer</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Opitz</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Wensel</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Agostoni P, Pellegrino R, Conca C, Rodarte JR, Brusasco V. Exercise hyperpnea in chronic heart failure: relationships to lung stiffness and expiratory flow limitation. J Appl Physiol. 2002; 92 (4): 1409-16.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Exercise hyperpnea in chronic heart failure: relationships to lung stiffness and expiratory flow limitation</article-title>
          <source>J Appl Physiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>1409</fpage>
          <lpage>16</lpage>
          <issue>4</issue>
          <volume>92</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Agostoni</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Pellegrino</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Conca</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Rodarte</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Brusasco</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Ponikowski P, Chua TP, Francis DP, Capucci A, Coats AJS, Piepoli MF. Muscle ergoreceptor overactivity reflects deterioration in clinical status and cardiorespiratory reflex control in chronic heart failure. Circulation. 2001; 104 (19): 2324-30.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Muscle ergoreceptor overactivity reflects deterioration in clinical status and cardiorespiratory reflex control in chronic heart failure</article-title>
          <source>Circulation</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>2324</fpage>
          <lpage>30</lpage>
          <issue>19</issue>
          <volume>104</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ponikowski</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Chua</surname>
              <given-names>TP</given-names>
            </name>
            <name>
              <surname>Francis</surname>
              <given-names>DP</given-names>
            </name>
            <name>
              <surname>Capucci</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Coats</surname>
              <given-names>AJS</given-names>
            </name>
            <name>
              <surname>Piepoli</surname>
              <given-names>MF</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Wang WZ, Gao L, Wang HJ, Zucker IH, Wang W. Interaction between cardiac sympathetic afferent reflex and chemoreflex is mediated by the NTS AT1 receptors in heart failure. Am J Physiol Heart Circ Physiol. 2008; 295 (3): H1216H1226.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Interaction between cardiac sympathetic afferent reflex and chemoreflex is mediated by the NTS AT1 receptors in heart failure</article-title>
          <source>Am J Physiol Heart Circ Physiol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>H1216</fpage>
          <lpage>H1226</lpage>
          <issue>3</issue>
          <volume>295</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>WZ</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Zucker</surname>
              <given-names>IH</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Guyton AC, Hall JE. Tratado de fisiologia m&#233;dica. 11&#350;. ed. S&#227;o Paulo: Elsevier; 2006.</mixed-citation>
        <element-citation publication-type="book">
          <source>Tratado de fisiologia m&#233;dica</source>
          <date>
            <year>2006</year>
          </date>
          <person-group person-group-type="author">
            <name>
              <surname>Guyton</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Hall</surname>
              <given-names>JE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Dibner-Dunlap ME, Smith ML, Kinugawa T, Thames MD. Enalaprilat augments arterial and cardiopulmonary baroreflex control of sympathetic nerve activity in patients with heart failure. J Am Coll Cardiol. 1996; 27 (2): 358-64.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Enalaprilat augments arterial and cardiopulmonary baroreflex control of sympathetic nerve activity in patients with heart failure</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>358</fpage>
          <lpage>64</lpage>
          <issue>2</issue>
          <volume>27</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Dibner-Dunlap</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Kinugawa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Thames</surname>
              <given-names>MD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Corr&#234;a LMA, Santos TSNP, Moura THP, Negr&#227;o CE. Altera&#231;&#245;es auton&#244;micas na insufici&#234;ncia card&#237;aca: benef&#237;cios do exerc&#237;cio f&#237;sico. Rev SOCERJ. 2008; 21 (2): 106-11.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Altera&#231;&#245;es auton&#244;micas na insufici&#234;ncia card&#237;aca: benef&#237;cios do exerc&#237;cio f&#237;sico</article-title>
          <source>Rev SOCERJ</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>106</fpage>
          <lpage>11</lpage>
          <issue>2</issue>
          <volume>21</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Corr&#234;a</surname>
              <given-names>LMA</given-names>
            </name>
            <name>
              <surname>Santos</surname>
              <given-names>TSNP</given-names>
            </name>
            <name>
              <surname>Moura</surname>
              <given-names>THP</given-names>
            </name>
            <name>
              <surname>Negr&#227;o</surname>
              <given-names>CE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Abboud FM, Thames MD. Interaction of cardiovascular reflexes in circulatory control. In: Sheperd JT, Abboud FM, Geiger SR. (editors). Handbook of physiology section 2: the cardiovascular system. Bethesda: American Physiological Society; 1983. p. 557-622.</mixed-citation>
        <element-citation publication-type="book">
          <source>Handbook of physiology section 2: the cardiovascular system</source>
          <date>
            <year>1983</year>
          </date>
          <fpage>557</fpage>
          <lpage>622</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Abboud</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Thames</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Sheperd</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Abboud</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Geiger</surname>
              <given-names>SR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Wade JG, Larson CP Jr, Hickey RF, Ehrenfeld WK, Severinghaus JW. Effect of carotid endarterectomy on carotid chemoreceptor and baroreceptor function in man. N Engl J Med. 1970; 282 (15): 823-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effect of carotid endarterectomy on carotid chemoreceptor and baroreceptor function in man</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>1970</year>
          </date>
          <fpage>823</fpage>
          <lpage>9</lpage>
          <issue>15</issue>
          <volume>282</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Wade</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Larson Jr</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Hickey</surname>
              <given-names>RF</given-names>
            </name>
            <name>
              <surname>Ehrenfeld</surname>
              <given-names>WK</given-names>
            </name>
            <name>
              <surname>Severinghaus</surname>
              <given-names>JW</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Lugliani RB, Whipp BJ, Seard C, Wasserman K. Effect of bilateral carotid-body resection on ventilatory control at rest and during exercise in man. N Engl J Med. 1971; 285 (20): 1105-11.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effect of bilateral carotid-body resection on ventilatory control at rest and during exercise in man</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>1971</year>
          </date>
          <fpage>1105</fpage>
          <lpage>11</lpage>
          <issue>20</issue>
          <volume>285</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lugliani</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Whipp</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Seard</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Wasserman</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Gelfand R, Lambertsen CJ. Dynamic respiratory response to abrupt change of inspired CO2 at normal and high PO2. J Appl Physiol. 1973; 35 (6): 903-13.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Dynamic respiratory response to abrupt change of inspired CO2 at normal and high PO2</article-title>
          <source>J Appl Physiol</source>
          <date>
            <year>1973</year>
          </date>
          <fpage>903</fpage>
          <lpage>13</lpage>
          <issue>6</issue>
          <volume>35</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gelfand</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lambertsen</surname>
              <given-names>CJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Narkiewicz K, Pesek CA, van de Borne PJH, Kato M, Somers VK. Enhanced sympathetic and ventilatory responses to central chemoreflex activation in heart failure. Circulation. 1999; 100 (3): 262-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Enhanced sympathetic and ventilatory responses to central chemoreflex activation in heart failure</article-title>
          <source>Circulation</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>262</fpage>
          <lpage>7</lpage>
          <issue>3</issue>
          <volume>100</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Narkiewicz</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Pesek</surname>
              <given-names>CA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Seals DR, Johnson DG, Fregosi RF. Hyperoxia lowers sympathetic nerve activity at rest but not during exercise in humans. Am J Physiol. 1991; 260 (5 Pt 2): R873-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Hyperoxia lowers sympathetic nerve activity at rest but not during exercise in humans</article-title>
          <source>Am J Physiol</source>
          <date>
            <year>1991</year>
          </date>
          <fpage>R873</fpage>
          <lpage>8</lpage>
          <issue>5 Pt 2</issue>
          <volume>260</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Seals</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Fregosi</surname>
              <given-names>RF</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Schultz HD, Sun SY. Chemoreflex function in heart failure. Heart Fail Rev. 2000; 5 (1): 45-56.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Chemoreflex function in heart failure</article-title>
          <source>Heart Fail Rev</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>45</fpage>
          <lpage>56</lpage>
          <issue>1</issue>
          <volume>5</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Schultz</surname>
              <given-names>HD</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>SY</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Duffin J. Role of acid-base balance in the chemoreflex control of breathing. J Appl Physiol. 2005; 99 (6): 2255-65.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Role of acid-base balance in the chemoreflex control of breathing</article-title>
          <source>J Appl Physiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>2255</fpage>
          <lpage>65</lpage>
          <issue>6</issue>
          <volume>99</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Duffin</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Ainslie PN, Duffin J. Integration of cerebrovascular CO2 reactivity and chemoreflex control of breathing: mechanisms of regulation, measurement and interpretation. Am J Physiol Regul Integr Comp Physiol. 2009; 296 (5): R1473-95.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Integration of cerebrovascular CO2 reactivity and chemoreflex control of breathing: mechanisms of regulation, measurement and interpretation</article-title>
          <source>Am J Physiol Regul Integr Comp Physiol</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>R1473</fpage>
          <lpage>95</lpage>
          <issue>5</issue>
          <volume>296</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ainslie</surname>
              <given-names>PN</given-names>
            </name>
            <name>
              <surname>Duffin</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24. Barrett KM, Ackerman RH, Gahn G, Romero JM, Candia M. Basilar and middle cerebral artery reserve: a comparative study using transcranial Doppler and breathholding techniques. Stroke. 2001; 32 (12): 2793-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Basilar and middle cerebral artery reserve: a comparative study using transcranial Doppler and breathholding techniques</article-title>
          <source>Stroke</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>2793</fpage>
          <lpage>6</lpage>
          <issue>12</issue>
          <volume>32</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Barrett</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Ackerman</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Gahn</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Romero</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Candia</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25. Atkinson JL, Anderson RE, Sundt TM Jr. The effect of carbon dioxide on the diameter of brain capillaries. Brain Res. 1990; 517 (12): 333-40.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The effect of carbon dioxide on the diameter of brain capillaries</article-title>
          <source>Brain Res</source>
          <date>
            <year>1990</year>
          </date>
          <fpage>333</fpage>
          <lpage>40</lpage>
          <issue>12</issue>
          <volume>517</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Atkinson</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Sundt Jr</surname>
              <given-names>TM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B26">
        <mixed-citation>26. Hanly P, Zuberi N, Gray R. Pathogenesis of Cheyne-Stokes respiration in patients with congestive heart failure: relationship to arterial PCO2. Chest. 1993; 104 (4): 1079-84.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Pathogenesis of Cheyne-Stokes respiration in patients with congestive heart failure: relationship to arterial PCO2</article-title>
          <source>Chest</source>
          <date>
            <year>1993</year>
          </date>
          <fpage>1079</fpage>
          <lpage>84</lpage>
          <issue>4</issue>
          <volume>104</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hanly</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Zuberi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Gray</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B27">
        <mixed-citation>27. Barreto-Filho JAS, Consolim-Colombo FM, Lopes HF, Martins Sobrinho CR, Guerra-Riccio GM, Krieger EM. Dysregulation of peripheral and central chemoreflex responses in chagas' heart disease patients without heart failure. Circulation. 2001; 104 (15): 1792-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Dysregulation of peripheral and central chemoreflex responses in chagas' heart disease patients without heart failure</article-title>
          <source>Circulation</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>1792</fpage>
          <lpage>8</lpage>
          <issue>15</issue>
          <volume>104</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Barreto-Filho</surname>
              <given-names>JAS</given-names>
            </name>
            <name>
              <surname>Consolim-Colombo</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Lopes</surname>
              <given-names>HF</given-names>
            </name>
            <name>
              <surname>Martins Sobrinho</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Guerra-Riccio</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Krieger</surname>
              <given-names>EM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B28">
        <mixed-citation>28. Barreto Filho JA. Quimiorreflexo na cardiopatia da doen&#231;a de Chagas. [Tese]. S&#227;o Paulo: Faculdade de Medicina da Universidade de S&#227;o Paulo; 1998.</mixed-citation>
        <element-citation publication-type="book">
          <source>Quimiorreflexo na cardiopatia da doen&#231;a de Chagas</source>
          <date>
            <year>1998</year>
          </date>
          <person-group person-group-type="author">
            <name>
              <surname>Barreto Filho</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B29">
        <mixed-citation>29. De Angelis K, Schaan BA, Rodrigues B, Malfitano C, Irigoyen MC. Disfun&#231;&#227;o auton&#244;mica cardiovascular no diabetes mellitus experimental. Arq Bras Endocrinol Metab. 2007; 51: 2.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Disfun&#231;&#227;o auton&#244;mica cardiovascular no diabetes mellitus experimental</article-title>
          <source>Arq Bras Endocrinol Metab</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>2</fpage>
          <volume>51</volume>
          <person-group person-group-type="author">
            <name>
              <surname>De Angelis</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Schaan</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Rodrigues</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Malfitano</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Irigoyen</surname>
              <given-names>MC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B30">
        <mixed-citation>30. Weisbrod CJ, Eastwood PR, O'Driscoll G, Green DJ. Abnormal ventilatory responses to hypoxia in Type 2 diabetes. Diab Med. 2005; 22 (5): 563-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Abnormal ventilatory responses to hypoxia in Type 2 diabetes</article-title>
          <source>Diab Med</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>563</fpage>
          <lpage>8</lpage>
          <issue>5</issue>
          <volume>22</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Weisbrod</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Eastwood</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>O'Driscoll</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Green</surname>
              <given-names>DJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B31">
        <mixed-citation>31. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) Study. Circulation. 2002; 106 (17); 2194-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) Study</article-title>
          <source>Circulation</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>2194</fpage>
          <lpage>9</lpage>
          <issue>17</issue>
          <volume>106</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Packer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fowler</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Roecker</surname>
              <given-names>EB</given-names>
            </name>
            <name>
              <surname>Coats</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Katus</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Krum</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B32">
        <mixed-citation>32. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) a randomized trial. Lancet. 1999; 353 (9146): 9-13.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) a randomized trial</article-title>
          <source>Lancet</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>9</fpage>
          <lpage>13</lpage>
          <issue>9146</issue>
          <volume>353</volume>
        </element-citation>
      </ref>
      <ref id="B33">
        <mixed-citation>33. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999; 353 (9169): 2001-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)</article-title>
          <source>Lancet</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>2001</fpage>
          <issue>9169</issue>
          <volume>353</volume>
        </element-citation>
      </ref>
      <ref id="B34">
        <mixed-citation>34. Greenberg B. Nonselective versus selective beta-blockers in the management of chronic heart failure: clinical implications of the carvedilol or metoprolol European Trial. Rev Cardiovasc Med. 2004; 5 (Suppl 1): S10-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Nonselective versus selective beta-blockers in the management of chronic heart failure: clinical implications of the carvedilol or metoprolol European Trial</article-title>
          <source>Rev Cardiovasc Med</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>S10</fpage>
          <lpage>7</lpage>
          <volume>5</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Greenberg</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B35">
        <mixed-citation>35. Remme WJ. Beta-blockade as first-line therapy in the elderly heart failure patient - the proper approach or asking for trouble? Cardiovasc Drugs Ther. 2008; 22 (5): 347-50.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Beta-blockade as first-line therapy in the elderly heart failure patient - the proper approach or asking for trouble</article-title>
          <source>Cardiovasc Drugs Ther</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>347</fpage>
          <lpage>50</lpage>
          <issue>5</issue>
          <volume>22</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Remme</surname>
              <given-names>WJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B36">
        <mixed-citation>36. Agostoni P, Contini M, Cattadori G, Apostolo A, Sciomer S, Bussotti M, et al. Lung function with carvedilol and bisoprolol in chronic heart failure: is beta selectivity relevant? Eur J Heart Fail. 2007; 9 (8): 827-33.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Lung function with carvedilol and bisoprolol in chronic heart failure: is beta selectivity relevant?</article-title>
          <source>Eur J Heart Fail</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>827</fpage>
          <lpage>33</lpage>
          <issue>8</issue>
          <volume>9</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Agostoni</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Contini</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cattadori</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Apostolo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sciomer</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bussotti</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B37">
        <mixed-citation>37. Puri S, Dutka DP, Baker BL, Hughes JMB, Cleland JGF. Acute saline infusion reduces alveolar-capillary membrane conductance and increases airflow obstruction in patients with left ventricular dysfunction. Circulation. 1999; 99 (9): 1190-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Acute saline infusion reduces alveolar-capillary membrane conductance and increases airflow obstruction in patients with left ventricular dysfunction</article-title>
          <source>Circulation</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>1190</fpage>
          <lpage>6</lpage>
          <issue>9</issue>
          <volume>99</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Puri</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Dutka</surname>
              <given-names>DP</given-names>
            </name>
            <name>
              <surname>Baker</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Hughes</surname>
              <given-names>JMB</given-names>
            </name>
            <name>
              <surname>Cleland</surname>
              <given-names>JGF</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B38">
        <mixed-citation>38. Witte KKA, Thackray SRD, Nikitin NP, Cleland JGF, Clark AL. The effects of alpha and beta blockade on ventilatory responses to exercise in chronic heart failure. Heart. 2003; 89 (10): 1169-73.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The effects of alpha and beta blockade on ventilatory responses to exercise in chronic heart failure</article-title>
          <source>Heart</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1169</fpage>
          <lpage>73</lpage>
          <issue>10</issue>
          <volume>89</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Witte</surname>
              <given-names>KKA</given-names>
            </name>
            <name>
              <surname>Thackray</surname>
              <given-names>SRD</given-names>
            </name>
            <name>
              <surname>Nikitin</surname>
              <given-names>NP</given-names>
            </name>
            <name>
              <surname>Cleland</surname>
              <given-names>JGF</given-names>
            </name>
            <name>
              <surname>Clark</surname>
              <given-names>AL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B39">
        <mixed-citation>39. Prabhakar NR, Peng YJ. Peripheral chemoreceptors in health disease. J Appl Physiol. 2004; 96 (1): 359-66.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Peripheral chemoreceptors in health disease</article-title>
          <source>J Appl Physiol</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>359</fpage>
          <lpage>66</lpage>
          <issue>1</issue>
          <volume>96</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Prabhakar</surname>
              <given-names>NR</given-names>
            </name>
            <name>
              <surname>Peng</surname>
              <given-names>YJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B40">
        <mixed-citation>40. Reid IA. Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexs in regulation of blood pressure. Am J Physiol. 1992; 262 (6 Pt 1): E763-78.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexs in regulation of blood pressure</article-title>
          <source>Am J Physiol</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>E763</fpage>
          <lpage>78</lpage>
          <issue>6</issue>
          <volume>262</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Reid</surname>
              <given-names>IA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B41">
        <mixed-citation>41. Li YL, Xia XH, Zheng H, Gao L, Li YF, Liu D, et al. Angiotensin II enhances carotid body chemoreflex control of sympathetic outflow in chronic heart failure rabbits. Cardiovasc Res. 2006; 71 (1): 129-38.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Angiotensin II enhances carotid body chemoreflex control of sympathetic outflow in chronic heart failure rabbits</article-title>
          <source>Cardiovasc Res</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>129</fpage>
          <lpage>38</lpage>
          <issue>1</issue>
          <volume>71</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>YL</given-names>
            </name>
            <name>
              <surname>Xia</surname>
              <given-names>XH</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>YF</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B42">
        <mixed-citation>42. Liu JL, Irvine S, Reid IA, Patel KP, Zucker IH. Chronic exercise reduces sympathetic nerve activity in rabbits with pacing-induced heart failure: a role for angiotensin II. Circulation. 2000; 102 (15): 1854-62.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Chronic exercise reduces sympathetic nerve activity in rabbits with pacing-induced heart failure: a role for angiotensin II</article-title>
          <source>Circulation</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>1854</fpage>
          <lpage>62</lpage>
          <issue>15</issue>
          <volume>102</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Irvine</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Reid</surname>
              <given-names>IA</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>KP</given-names>
            </name>
            <name>
              <surname>Zucker</surname>
              <given-names>IH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B43">
        <mixed-citation>43. van deWal RM, Plokker HW, Lok DJ, Boomsma F, van der Horst FA, van Veldhuisen DJ, et al. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol. 2006; 106 (3): 367-72.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition</article-title>
          <source>Int J Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>367</fpage>
          <lpage>72</lpage>
          <issue>3</issue>
          <volume>106</volume>
        </element-citation>
      </ref>
      <ref id="B44">
        <mixed-citation>44. Li YL, Schultz HD. Enhanced sensitivity of Kv channels to hypoxia in the rabbit carotid body in heart failure: role of angiotensin II. J Physiol. 2006; 575 (1): 215-27.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Enhanced sensitivity of Kv channels to hypoxia in the rabbit carotid body in heart failure: role of angiotensin II</article-title>
          <source>J Physiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>215</fpage>
          <lpage>27</lpage>
          <issue>1</issue>
          <volume>575</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>YL</given-names>
            </name>
            <name>
              <surname>Schultz</surname>
              <given-names>HD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Behavior of central and peripheral chemoreflexes in heart failure</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>The heart failure (HF) syndrome can be defined as the final pathway of any type of heart disease. The sympatho-inhibitory cardiovascular reflexes, such as the arterial baroreceptor reflex, are significantly decreased in HF. Patients with HF present higher ventilation for a certain workload when compared with normal individuals. This fact generates low ventilatory efficiency and is related to higher ventilation associated with the carbon dioxide production, which is a predictor of bad prognosis, in addition to being a limiting factor for the practice of exercises. There is evidence that the autonomic imbalance contributes to the pathogenesis and the progression of heart failure. The chemoreflexes are the main mechanisms of control and regulation of the ventilatory responses to the changes in concentrations of arterial oxygen and carbon dioxide. The chemoreflex activation causes an increase in the sympathetic activity, heart rate, arterial pressure and minute volume. However, the increase in the minute volume and the arterial pressure, due to negative feedback, cause inhibition of the sympathetic response at the chemoreflex activation. In spite of the functional alterations of the reflexes, their behavior in normal and pathological conditions, especially their contribution to the sympathoexcitatory state observed in HF has not been broadly studied. Therefore, this review aims at integrating the knowledge on central and peripheral chemoreflexes in HF syndrome, as well as clarifying the influence of the heart failure drug therapy on the chemoreflexes.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Heart failure</kwd>
        <kwd>autonomic nervous system</kwd>
        <kwd>baroreflex</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p><undefined id="tx-body2"/>Behavior of central and peripheral chemoreflexes in heart failure</p>
      <p>
        <bold>Guilherme Veiga Guimar&#227;es<sup>I,II</sup>; Juliana Fernanda Canhadas Belli<sup>I,II</sup>; Fernando Bacal<sup>I</sup>; Edimar Alcides Bocchi<sup>I</sup></bold>
      </p>
      <p><sup>I</sup>Instituto do Cora&#231;&#227;o do Hospital das Cl&#237;nicas da Faculdade de Medicina da Universidade de S&#227;o Paulo</p>
      <p><sup>II</sup>Laborat&#243;rio de Atividade F&#237;sica e Sa&#250;de do Centro de Pr&#225;ticas Esportivas da Universidade de S&#227;o Paulo, S&#227;o Paulo, SP - Brazil</p>
      <p>Mailing address</p>
      <p>
        <bold>ABSTRACT</bold>
      </p>
      <p>The heart failure (HF) syndrome can be defined as the final pathway of any type of heart disease. The sympatho-inhibitory cardiovascular reflexes, such as the arterial baroreceptor reflex, are significantly decreased in HF. Patients with HF present higher ventilation for a certain workload when compared with normal individuals. This fact generates low ventilatory efficiency and is related to higher ventilation associated with the carbon dioxide production, which is a predictor of bad prognosis, in addition to being a limiting factor for the practice of exercises. There is evidence that the autonomic imbalance contributes to the pathogenesis and the progression of heart failure. The chemoreflexes are the main mechanisms of control and regulation of the ventilatory responses to the changes in concentrations of arterial oxygen and carbon dioxide. The chemoreflex activation causes an increase in the sympathetic activity, heart rate, arterial pressure and minute volume. However, the increase in the minute volume and the arterial pressure, due to negative feedback, cause inhibition of the sympathetic response at the chemoreflex activation. In spite of the functional alterations of the reflexes, their behavior in normal and pathological conditions, especially their contribution to the sympathoexcitatory state observed in HF has not been broadly studied.</p>
      <p>Therefore, this review aims at integrating the knowledge on central and peripheral chemoreflexes in HF syndrome, as well as clarifying the influence of the heart failure drug therapy on the chemoreflexes.</p>
      <p><bold>Keywords:</bold> Heart failure/therapy; autonomic nervous system; baroreflex/drugs effects.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>The heart failure (HF) syndrome can be defined as the final pathway of any type of heart disease<sup>1</sup>, in which structural, functional and neurohumoral disorders of the heart lead to the decrease in the capacity of the ventricle to eject and/or fill with blood at the physiological filling pressures<sup>1,2</sup>. These alterations result in systolic and/or diastolic dysfunction and, consequently, in the loss of functional capacity, decrease in quality of life and increased morbidity and mortality<sup>3,4</sup>. </p>
      <p>The HF syndrome is associated with hemodynamic disorders followed by systemic alterations, endothelial dysfunction, neurohormonal activation with increased catecholamine release, higher brain natriuretic peptide (BNP) levels<sup>5</sup> and release of pro-inflammatory factors that contribute to heart dilation and poorer performance at physical exercises<sup>5,6</sup>. Patients with HF present higher levels of ventilation for a certain workload when compared to normal individuals<sup>7</sup>. This fact results in low ventilatory efficiency and is related with higher ventilation related to CO<sub>2</sub> production, which is an important predictor of poor prognosis, in addition to being a limiting factor for the practice of exercises<sup>8,9</sup>.</p>
      <p>Hyperventilation can occur due to several causes and among them, a hyperactive chemoreceptor reflex, one of the several abnormalities in the cardiovascular reflex control related to the increased sympathetic tonus in HF<sup>7,10</sup>. The signal hyperactivation originated from the receptors located in the skeletal muscles (mechanoreceptors - metaboreceptors) is a recently proposed hypothesis to explain the origin of symptoms of intolerance to physical exertion<sup>8</sup>.</p>
      <p>The sympathoinhibitory cardiovascular reflexes, such as the arterial baroreceptor reflex, are significantly suppressed in HF. In turn, the sympathoexcitatory reflexes, including the arterial chemoreceptor reflex and the sympatho-afferent cardiac reflexes, are increased in HF. Although the functional alterations of the reflexes have been used independently to illustrate the sympathetic excitation observed in HF, the interaction between these reflexes in normal and pathological conditions, especially their contribution to the sympathoexcitatory state found in HF, has not been broadly studied<sup>11</sup>. Therefore, the objective of this study is to carry out a review of the action mechanism of peripheral and central chemoreceptors.</p>
      <p>
        <bold>Cardiopulmonary regulation</bold>
      </p>
      <p>The cardiopulmonary recptores are located, basically, in association with the large arterial vessels in the chest and neck and transmit stimuli to the respiratory center to help regulate the respiratory activity. Most of them are found in the aortic and carotid bodies, along their afferent nervous connections with the respiratory cento. The carotid bodies are located bilaterally in the bifurcations of the main carotid arteries and their afferent fibers pass through Hering's nerves to the glossopharyngeal nerves and then to the medulla oblongata. The aortic bodies are located along the aortic arch and their nervous fibers pass into the medulla oblongata through the vagus nerve and then to the spinal cord through the sympathetic nerves<sup>12</sup> (<xref ref-type="fig" rid="fig01-body2">Figure 1</xref>). Three sets of cardiopulmonary receptors can be identified: 1) non-myelinated vagal cardiac afferents, which are small nervous terminals scattered in the cardiac chambers, sensitive to mechanical distension due to alterations in the atrial pressure or diastolic-end pressure and, as they cause similar responses to the arterial baroreceptors, it is supposed that both use the same neuronal pathways; 2) myelinated vagal cardiac afferents, located especially at the junction of large vessels and atria, spontaneously active during systole and diastole and that supply information to the central nervous system on the degree of atrial filling and heart rate. In situations of increased volemia, they cause a decrease in the renal sympathetic nervous activity and, consequently, a decrease in the release of vasopressin by the neurohypophysis. In this condition there is also an increase in the levels of brain natriuretic peptide (BNP) levels, which induces increases in diuresis and natriuresis, in addition to the inhibition of renin and aldosterone release and 3) spinal afferents of which trajectory coincides with that of sympathetic ones and are distributed along the coronary arteries, the cardiac chambers and great vessels of the chest. </p>
      <fig id="fig01-body2">
        <graphic xlink:href="1678-4170-abc-96-02-0161-00003-gf01-en.jpg"/></fig>
      <p>
        <bold>Chemoreflex control</bold>
      </p>
      <p>The autonomous nervous system allows the body to adjust its circulation and ventilation to maintain the oxygen supply to the tissues. The autonomic balance is maintained by the complex interaction of the arterial baroreflex, central and peripheral chemoreflex, ergoreflex and lung stretch reflex (<xref ref-type="fig" rid="fig02-body2">Figure 2</xref>). There is evidence that the autonomic imbalance contributes to the pathogenesis and progression of heart failure<sup>15</sup>.</p>
      <fig id="fig02-body2">
        <graphic xlink:href="1678-4170-abc-96-02-0161-00003-gf02-en.jpg"/></fig>
      <p>The chemoreflexes are the main mechanisms of control and regulation of the ventilatory responses to the changes in arterial oxygen and CO<sub>2</sub> concentrations<sup>16</sup>. The peripheral chemoreceptors located in the carotid and aortic bodies, with afferents to the respiratory center in the medulla oblongata and the nucleus of the solitary tract, respond primarily to hypoxia<sup>16,17</sup>. The central chemoreceptors, located on the ventral surface of the spinal cord, respond primarily to hypercapnia<sup>18</sup>. Both responses to alterations in the concentrations of O<sub>2</sub> and CO<sub>2</sub>, respectively, increase pulmonary ventilation. Almost simultaneously, another set of neurons that reach the nucleus of the solitary tract induces the increase in the sympathetic nervous activity. Both chemoreceptor mechanisms have a strong influence on neural control of circulation, especially in situations involving significant changes in the arterial concentrations of oxygen and/or CO<sub>2</sub>. The chemoreflex activation causes an increase in the sympathetic activity, heart rate, arterial pressure and minute volume. However, the increase in the minute volume and the arterial pressure, by negative feedback, causes inhibition of the sympathetic response to the chemoreflex activation. Therefore, chemoreflexes trigger several cardiovascular and respiratory responses, with complex interactions between their responses. To define any abnormality in the chemoreflex function, it is essential to consider the individual contribution of each component that integrates this response. In patients with HF, the stimulation of the central and peripheral chemoreceptors causes a marked increase in pulmonary ventilation and the sympathetic nervous activity, characterized by a selective potentiation of these responses<sup>14,19</sup>.</p>
      <p>
        <bold>Contribution of the chemoreceptors under normoxia</bold>
      </p>
      <p>The chemoreflexes (central and peripheral) have a crucial role in the control of alveolar ventilation to guarantee that the gas exchanges in the lungs continuously supply the metabolic demand through the oxygen uptake and CO<sub>2</sub> removal. </p>
      <p>Frequently overestimated, however, is the fact that these reflexes also have a significant effect on the cardiac and vascular control to regulate the blood flow and then the levels of tissue gas exchange. An important component for the activation of the chemoreflex is an increase in the sympathetic activity on the vascular beds. This response helps the maintenance of the arterial pressure in the presence of the direct vasodilating effects of hypoxemia or hypercapnia and then helps to maintain the pressure adequate for the blood flow and tissue gas exchange. </p>
      <p>The idea that the chemoreflexes contribute to the sympathetic activity at rest in pathological states has been the hypothesis that the chemoreflexes would not be activated at rest (normoxia and isocapnia) and, therefore, they would have little influence on the sympathetic tonus under normal conditions. However, this hypothesis is quite controversial. In normal individuals at rest, the hyperoxia, which inhibits the activity of peripheral echemoreceptors, decreases the sympathetic nervous activity<sup>20</sup>. However, individuals with sleep apnea present an increased chemoreflex activity under normoxia. Thus, it can be suggested that the chemoreflexes contribute to the increased sympathetic tonus in heart failure, even in the absence of hypoxia<sup>21</sup>.</p>
      <p>
        <bold>Chemoreflexes and ventilatory abnormalities</bold>
      </p>
      <p>The respiration is stimulated by the chemoreflexes that include the central and peripheral receptors, the central nervous system and the respiratory muscles. The chemoreflexes are part of the negative feedback of a feedback cycle. The cycle is completed by the progression in which the alveolar ventilation controls the O<sub>2</sub> extraction and the elimination of CO<sub>2</sub>. The cycle progression associates the dependence of PCO<sub>2</sub> and PO<sub>2</sub> in ventilation<sup>22</sup>. The simulation of chemoreceptors results in an increased alveolar ventilation that leads to an increased elimination of CO<sub>2</sub> and decrease in PCO<sub>2</sub>, stimulating the chemoreceptors por meiothrough the increased concentration of H<sup>+</sup> ions; therefore, concluding the negative feedback designation of the system<sup>23</sup> (<xref ref-type="fig" rid="fig03-body2">Figure 3</xref>).</p>
      <fig id="fig03-body2">
        <graphic xlink:href="1678-4170-abc-96-02-0161-00003-gf03-en.jpg"/></fig>
      <p>The increased sensitivity of the central and peripheral chemoreflexes can have an important role in the ventilatory control alteration observed in heart failure and a significant correlation can be found between the ventilatory response to exercise and the hypoxic chemosensitivity at rest<sup>24</sup>. The inhibition of the peripheral chemoreflex has been shown to increase the performance at exercise and decrease the ventilatory response in patients with HF. These observations suggest that the marked hyperpnea at exercise can be influenced by the increased peripheral chemoreflex activity in these patients<sup>25,26</sup>.</p>
      <p>A significant positive correlation was observed between the central hypercapnic ventilatory response and the sleep time percentage in patients with HF and Cheyne-Stokes respiration. The fact that supplemental O<sub>2 </sub>ane CO<sub>2</sub> during sleep increase the Cheyne-Stokes respiration suggests a contribution of the increased chemosensitivity in this disorder. This increase can also explains the tendency of lower-than-normal PaCO<sub>2</sub> obseraes during sleep and wakefulness in individuals with Cheyne-Stokes respiration<sup>26</sup>.</p>
      <p>In heart failure of Chagasic etiology, the ventilatory and autonomic responses increased with the stimulation of the peripheral chemoreflex. On the other hand, the ventilatory and autonomic responses decreased during hypercapnia, associated with the activation of central chemoreceptors in this group of patients<sup>27,28</sup>.</p>
      <p>Additionally, it is worth mentioning that, together with Chagas' disease, diabetes mellitus is a disease that can course with autonomic neuropathy, leading to dysautonomy and very often, patients with HF present diabetes as a comorbidity.</p>
      <p>There have been few studies associating diabetes and the chemoreflex function. Studies with experimental models have shown that the chemoreflex is decreased<sup>29</sup>. In humans, it has been observed a decrease in the peripheral chemoreflex in individuals with type 2 diabetes, especially regarding the response to hypoxia<sup>30</sup>.</p>
      <p>
        <bold>Influence of drug therapy on the central and peripheral chemoreflexes</bold>
      </p>
      <p>The drug therapy is crucial for a better prognosis in HF. The current treatment of HF includes beta-blockers (BB), angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB). The treatment with beta-blockers significantly altered the morbidity and mortality of patients with HF, as shown in the COPERNICUS<sup>31</sup>, CIBIS-II<sup>32</sup> and MERIT-HF studies<sup>33</sup>. The beta-blockers decrease the progression of left ventricular dysfunction, decrease the sympathetic activity and thus improve the prognosis of patients HF<sup>34</sup>. Their beneficial effects are evident, regardless of age or the low, intermediate or high risk that the patients present for HF<sup>35</sup>. However, that is not translated into exercise capacity improvement, at either submaximal or maximal exertion. </p>
      <p>The beta-blockers can act on the beta-1 and/or beta-2 adrenergic receptors. The respiratory system is characterized by a prevalence of beta-2 receptors, which are characterized by regulating the bronchial tonus, whereas the alveolar beta receptors regulate the reabsorption of fluids that affect gas diffusion; however, more than 90% of the beta receptors are located in the alveoli, in which the beta-2 type predominate (70%)<sup>36,37</sup>. Although the treatment with beta-blockers is an effective therapy for HF, to date, only a few studies have evaluated the effect of beta-blockers on exercise-induced hyperventilation<sup>38</sup>. Additionally, there are no data regarding the effect of beta-blockers during exercise under hypoxia, when the arterial hypoxemia increases the activity of the chemoreceptors<sup>39</sup>. </p>
      <p>The angiotensin-converting enzyme inhibitors (ACEI) inhibit the conversion of angiotensin I (AI) into angiotensin II (AII), decreasing the levels of the latter in the blood. The formation of AII involves the sequential cleavage of angiotensinogen. The angiotensinogen is transformed into angiotensin I through the action of renin, synthesized by the kidney, and then it is hydrolyzed into angiotensin II, through the action of the angiotensin-converting enzyme (ACE). The renin-angiotensin-aldosterone system can be blocked at different places and by several mechanism. The angiotensin-converting enzyme activity is predominantly found in the endothelium of lung vessels. The angiotensin II promotes aldosterone release by the adrenal glands. The agents that inhibit ACE interfere with the conversion of AI into AII, the latter being considered one of the most important systemic hormones, among which are noradrenaline, vasopressin and endothelin.</p>
      <p>The angiotensin II receptor blockers (ARB) are drugs that act on AT1 receptors, responsible for all known actions of AII, including vasoconstriction, aldosterone release and effects on the myocardium and vasculature (<xref ref-type="fig" rid="en_165fig04-body2">Figure 4</xref>). There are hypotheses to explain their influence on the dynamics of central and peripheral chemoreflexes. Although the cell and molecular mechanisms involved in the increased sensitivity of the carotid chemoreceptors during HF are yet to be elucidated, there is evidence that the increased levels of angiotensin II in the central nervous system accentuates the peripheral chemoreflex sensitivity and increases the peripheral sympathetic nervous activity<sup>40,41</sup>.</p>
      <p content-type="asset">
        <fig id="en_165fig04-body2">
          <graphic xlink:href="1678-4170-abc-96-02-0161-00003-gf04-en.jpg"/></fig>
      </p>
      <p>The plasma and tissue levels of angiotensin II are increased in HF and, moreover, some studies have associated the hypersensitivity of chemoreceptors in HF to the increased levels of AII and the decreased levels of nitric oxide<sup>42,43</sup>.</p>
      <p>Recent studies demonstrated that the endogenous levels of AII and the expression of AT1 receptors are increased in the carotid bodies in animal models of HF and that mediates the increased sensitivity of chemoreceptors to hypoxia. Therefore, the drug treatment of with ARB can affect the chemoreflexes in HF, but most studies are experimental animal models, which limits the extrapolation of these conclusions regarding these mechanisms to humans<sup>41,44</sup>.</p>
      <p>
        <bold>Perspectives</bold>
      </p>
      <p>In spite of the divergent results, currently the evidence points out to an increase in the activity of central and peripheral chemoreflexes in HF, which is correlated with disease severity. Although the mechanisms responsible for the altered central chemoreflex sensitivity are still unclear, the resulting alterations can be responsible, in part, for the increased ventilatory response at exercise, dyspnea, Cheyne-Stokes respiration and sympathetic hyperactivation observed in heart failure. As for the drugs used in the clinical management of HF, although they decrease the sympathetic hyperstimulation and the sensitivity of the central and peripheral chemoreflexes, they do not improve exercise performance, even if they attenuate symptoms such as dyspnea. </p>
      <p>Therefore, the genesis of the signs and symptoms of the heart failure syndrome requires further clarification, so that we can intervene and treat the syndrome in order to improve prognosis, quality of life and the performance at activities of daily living. </p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This study is not associated with any post-graduation program.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Comportamiento de los quimiorreflejos central y perif&#233;rico en la insuficiencia card&#237;aca</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>El s&#237;ndrome de insuficiencia card&#237;aca (IC) puede ser definido como v&#237;a final de cualquier forma de enfermedad card&#237;aca. Los reflejos cardiovasculares simp&#225;ticoinhibitorios como el reflejo arterial barorreceptor est&#225;n significativamente suprimidos en la IC. Pacientes con IC presentan mayor ventilaci&#243;n para determinada carga de trabajo cuando son comparados a individuos normales. Ese hecho genera baja eficiencia ventilatoria y se relaciona con mayor ventilaci&#243;n relativa a la producci&#243;n de gas carb&#243;nico, que es un predictor de mal pron&#243;stico, adem&#225;s de ser un factor limitante del ejercicio. Hay evidencias de que el desequilibrio auton&#243;mico contribuya a la patog&#233;nesis y la progresi&#243;n de la insuficiencia card&#237;aca. Los quimiorreflejos son los principales mecanismos de control y regulaci&#243;n de las respuestas ventilatorias a los cambios de concentraci&#243;n del ox&#237;geno y gas carb&#243;nico arterial. La activaci&#243;n del quimiorreflejo causa aumento de la actividad simp&#225;tica, frecuencia card&#237;aca, presi&#243;n arterial y volumen minuto. Mientras tanto, el aumento del volumen minuto y de la presi&#243;n arterial, por el feedback negativo provocan inhibici&#243;n de la respuesta simp&#225;tica a la activaci&#243;n del quimiorreflejo. A pesar de las alteraciones funcionales de los reflejos, su comportamiento en condiciones normales y patol&#243;gicas, especialmente su contribuci&#243;n al estado simp&#225;ticoexcitatorio encontrado en la IC, no ha sido ampliamente estudiado. De esa forma, esta revisi&#243;n tiene por objetivo integrar los conocimientos respecto a los quimiorreflejos central y perif&#233;rico en el s&#237;ndrome de insuficiencia card&#237;aca, as&#237; como aclarar la influencia de la terap&#233;utica medicamentosa de la insuficiencia card&#237;aca en los quimiorreflejos.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Insuficiencia card&#237;aca</kwd>
        <kwd>sistema Nervioso Aut&#243;nomo</kwd>
        <kwd>Barorreflejo</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO DE REVISI&#211;N</bold>
      </p>
      <p>
        <fn id="enda-body3">
          <label>
            <bold>Comportamiento de los quimiorreflejos central y perif&#233;rico en la insuficiencia card&#237;aca</bold>
          </label>
          <p>
            <bold>Guilherme Veiga Guimar&#227;es<sup>I,II</sup>; Juliana Fernanda Canhadas Belli<sup>I,II</sup>; Fernando Bacal<sup>I</sup>; Edimar Alcides Bocchi<sup>I</sup></bold>
          </p>
        </fn>
      </p>
      <p><sup>I</sup>Instituto do Cora&#231;&#227;o do Hospital das Cl&#237;nicas da Faculdade de Medicina da Universidade de S&#227;o Paulo</p>
      <p><sup>II</sup>Laborat&#243;rio de Atividade F&#237;sica e Sa&#250;de do Centro de Pr&#225;ticas Esportivas da Universidade de S&#227;o Paulo, S&#227;o Paulo, SP - Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p>El s&#237;ndrome de insuficiencia card&#237;aca (IC) puede ser definido como v&#237;a final de cualquier forma de enfermedad card&#237;aca. Los reflejos cardiovasculares simp&#225;ticoinhibitorios como el reflejo arterial barorreceptor est&#225;n significativamente suprimidos en la IC. Pacientes con IC presentan mayor ventilaci&#243;n para determinada carga de trabajo cuando son comparados a individuos normales. Ese hecho genera baja eficiencia ventilatoria y se relaciona con mayor ventilaci&#243;n relativa a la producci&#243;n de gas carb&#243;nico, que es un predictor de mal pron&#243;stico, adem&#225;s de ser un factor limitante del ejercicio. Hay evidencias de que el desequilibrio auton&#243;mico contribuya a la patog&#233;nesis y la progresi&#243;n de la insuficiencia card&#237;aca. Los quimiorreflejos son los principales mecanismos de control y regulaci&#243;n de las respuestas ventilatorias a los cambios de concentraci&#243;n del ox&#237;geno y gas carb&#243;nico arterial. La activaci&#243;n del quimiorreflejo causa aumento de la actividad simp&#225;tica, frecuencia card&#237;aca, presi&#243;n arterial y volumen minuto. Mientras tanto, el aumento del volumen minuto y de la presi&#243;n arterial, por el <italic>feedback</italic> negativo provocan inhibici&#243;n de la respuesta simp&#225;tica a la activaci&#243;n del quimiorreflejo. A pesar de las alteraciones funcionales de los reflejos, su comportamiento en condiciones normales y patol&#243;gicas, especialmente su contribuci&#243;n al estado simp&#225;ticoexcitatorio encontrado en la IC, no ha sido ampliamente estudiado. De esa forma, esta revisi&#243;n tiene por objetivo integrar los conocimientos respecto a los quimiorreflejos central y perif&#233;rico en el s&#237;ndrome de insuficiencia card&#237;aca, as&#237; como aclarar la influencia de la terap&#233;utica medicamentosa de la insuficiencia card&#237;aca en los quimiorreflejos.</p>
      <p><bold>Palabras clave:</bold> Insuficiencia card&#237;aca / terapia, sistema Nervioso Aut&#243;nomo, Barorreflejo / efectos de drogas.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>El s&#237;ndrome de la insuficiencia card&#237;aca (IC) puede ser definido como la v&#237;a final de cualquier forma de enfermedad card&#237;aca<sup>1</sup>, en la cual des&#243;rdenes estructurales, funcionales y neurohumorales del coraz&#243;n llevan a la disminuci&#243;n de la capacidad del ventr&#237;culo de eyectar y/o de llenarse de sangre en las presiones de llenado fisiol&#243;gicas<sup>1,2</sup>. Esas alteraciones resultan en disfunci&#243;n card&#237;aca sist&#243;lica, diast&#243;lica o ambas y, consecuentemente, p&#233;rdida de la capacidad funcional, disminuci&#243;n de la calidad de vida y aumento de la morbilidad y mortalidad<sup>3,4</sup>. </p>
      <p>El s&#237;ndrome de insuficiencia card&#237;aca se asocia a disturbios hemodin&#225;micos seguidos de alteraciones sist&#233;micas, disfunci&#243;n endotelial, activaci&#243;n neurohormonal, con aumento en la liberaci&#243;n de catecolaminas, mayores niveles de p&#233;ptido natriur&#233;tico cerebral (BNP-B)<sup>5</sup> y liberaci&#243;n de factores proinflamatorios que contribuyen a la dilataci&#243;n card&#237;aca y menor desempe&#241;o frente al ejercicio f&#237;sico<sup>5,6</sup>. Pacientes con IC presentan mayor ventilaci&#243;n para determinada carga de trabajo cuando son comparados a individuos normales<sup>7</sup>. Ese hecho genera baja eficiencia ventilatoria y se relaciona con mayor ventilaci&#243;n relativa a la producci&#243;n de gas carb&#243;nico que es un importante predictor de mal pron&#243;stico, adem&#225;s de ser un factor limitante del ejercicio<sup>8,9</sup>. </p>
      <p>La hiperventilaci&#243;n puede ocurrir por diversas causas, entre ellas la hiperactividad de los reflejos venidos de quimiorreceptores, una de las diversas anormalidades en el control reflejo cardiovascular relacionado al tono simp&#225;tico aumentado en la IC<sup>7,10</sup>. La hiperactivaci&#243;n de las se&#241;ales originadas en los receptores ubicados en los m&#250;sculos esquel&#233;ticos (mecanorreceptores - metaborreceptores) es una hip&#243;tesis propuesta recientemente para explicar el origen de los s&#237;ntomas de intolerancia al esfuerzo f&#237;sico<sup>6</sup>. </p>
      <p>Los reflejos cardiovasculares simp&#225;ticoinhibitorios como el reflejo arterial barorreceptor est&#225;n significativamente suprimidos en la IC. A su vez, los reflejos simp&#225;ticoexcitatorios, incluyendo el reflejo de los quimiorreceptores arteriales y los reflejos card&#237;acos simp&#225;ticoaferentes, est&#225;n aumentados en la IC. A pesar de que las alteraciones funcionales de los reflejos hayan sido usadas de manera independiente para ilustrar la excitaci&#243;n simp&#225;tica observada en la IC, la interacci&#243;n entre esos reflejos en condiciones normales y patol&#243;gicas, especialmente su contribuci&#243;n al estado simp&#225;ticoexcitatorio encontrado en la IC, no han sido ampliamente estudiados<sup>11</sup>. As&#237;, el objetivo este art&#237;culo es hacer una revisi&#243;n l respecto del mecanismo de acci&#243;n de los quimiorreflejos perif&#233;rico y central. </p>
      <p>
        <bold>Regulaci&#243;n cardiopulmonar </bold>
      </p>
      <p>Los receptores cardiopulmonares se ubican, b&#225;sicamente, en asociaci&#243;n con los grandes vasos arteriales del t&#243;rax y del cuello y transmiten est&#237;mulos al centro respiratorio, para ayudar a regular la actividad respiratoria. La mayor&#237;a de ellos se encuentra en los corp&#250;sculos a&#243;rticos y carot&#237;deos, a lo largo de sus conexiones nerviosas aferentes con el centro respiratorio. Los corp&#250;sculos carot&#237;deos se ubican bilateralmente en las bifurcaciones de las arterias car&#243;tidas principales y sus fibras aferentes pasan a trav&#233;s de los nervios de Hering hacia los nervios glosofar&#237;ngeos y de all&#237; al bulbo. Los corp&#250;sculos a&#243;rticos se ubican a lo largo del cayado de la aorta y sus fibras nerviosas pasan al bulbo a trav&#233;s del nervio vago y a la medula espinal v&#237;a nervios simp&#225;ticos<sup>12</sup> (<xref ref-type="fig" rid="fig1-body3">Figura 1</xref>). Tres conjuntos de receptores cardiopulmonares pueden ser identificados: 1) aferentes card&#237;acos vagales no mielinizados, que son peque&#241;as terminaciones nerviosas dispersas en las c&#225;maras card&#237;acas, sensibles a la distensi&#243;n mec&#225;nica por alteraciones en la presi&#243;n atrial o en la presi&#243;n diast&#243;lica final, y por provocar respuestas semejantes a los barorreceptores arteriales se supone que ambos utilicen las mismas v&#237;as neuronales; 2) aferentes card&#237;acos vagales mielinizados, ubicados especialmente en la uni&#243;n de las grandes venas y atrios, espont&#225;neamente activos durante la s&#237;stole y la di&#225;stole, y que proveen informaciones al sistema nervioso central sobre el grado de llenado atrial y la frecuencia card&#237;aca. En situaciones de aumento de la volemia, provocan reducci&#243;n en la actividad nerviosa simp&#225;tica renal y, consecuentemente, disminuci&#243;n en la liberaci&#243;n de vasopresina por la neurohip&#243;fisis. En esa condici&#243;n, ocurre tambi&#233;n aumento en los niveles de p&#233;ptido natriur&#233;tico atrial, lo que induce elevaciones en la diuresis y en la natriuresis, adem&#225;s de inhibici&#243;n de la liberaci&#243;n de renina y aldosterona; y 3) aferentes espinales que corren junto al simp&#225;tico y est&#225;n distribuidos a lo largo de las arterias coronarias, de las c&#225;maras card&#237;acas y de los grandes vasos tor&#225;cicos. As&#237;, sus fibras aferentes caminan junto a los nervios card&#237;acos simp&#225;ticos hasta la medula espinal y sus cuerpos celulares est&#225;n presentes en los ganglios de la ra&#237;z dorsal. Aunque sean activados por est&#237;mulos mec&#225;nicos, como ca&#237;das en la presi&#243;n de perfusi&#243;n de las coronarias, induciendo vasodilataci&#243;n en situaciones isqu&#233;micas, y por sustancias qu&#237;micas que act&#250;an directamente en el epicardio, tales como bradicinina, &#225;cidos org&#225;nicos y cloruro de potasio, ejercen un papel protector importante en la se&#241;alizaci&#243;n de sensaciones dolorosas, como en las de crisis de angina<sup>5</sup>. En la IC, el control reflejo cardiopulmonar est&#225; sensiblemente alterado en raz&#243;n de la respuesta nerviosa simp&#225;tica refleja desencadenada porque el llenado card&#237;aco est&#225; significativamente disminuido en esos pacientes<sup>13,14</sup>. </p>
      <fig id="fig1-body3">
        <graphic xlink:href="1678-4170-abc-96-02-0161-00003-gf01-es.jpg"/></fig>
      <p>
        <bold>Control quimiorreflejo </bold>
      </p>
      <p>El sistema nervioso aut&#243;nomo permite al organismo ajustar su circulaci&#243;n y ventilaci&#243;n para mantener el aporte de ox&#237;geno a los tejidos. El equilibrio auton&#243;mico es mantenido por la compleja interacci&#243;n del barorreflejo arterial, quimiorreflejo central y perif&#233;rico, ergorreflexo y reflejo de estiramiento pulmonar (<xref ref-type="fig" rid="es_a12fig02m-body3">Figura 2</xref>). Hay evidencias de que el desequilibrio auton&#243;mico contribuya a la patog&#233;nesis y progresi&#243;n de la insuficiencia card&#237;aca<sup>15</sup>. </p>
      <p content-type="asset">
        <fig id="es_a12fig02m-body3">
          <graphic xlink:href="1678-4170-abc-96-02-0161-00003-gf02-es.jpg"/></fig>
      </p>
      <p>Los quimiorreflejos son los principales mecanismos de control y regulaci&#243;n de las respuestas ventilatorias a las cambios de concentraci&#243;n del ox&#237;geno y gas carb&#243;nico arterial<sup>16</sup>. Los quimiorreceptores perif&#233;ricos ubicados en los cuerpo carot&#237;deos y a&#243;rtico, con aferencias hacia el centro respiratorio en el bulbo y hacia el n&#250;cleo del tracto solitario, responden primariamente a la hipoxia<sup>16,17</sup>. Los quimiorreceptores centrales, ubicados en la superficie ventral de la medula espinal, responden primariamente a la hipercapnia<sup>18</sup>. Ambas respuestas a las alteraciones de la concentraci&#243;n de O<sub>2</sub> y CO<sub>2</sub> respectivamente, aumentan la ventilaci&#243;n pulmonar. Casi simult&#225;neamente, otro conjunto de neuronas que llega al n&#250;cleo del tracto solitario induce aumento en la actividad nerviosa simp&#225;tica. Ambos mecanismos quimiorreceptores ejercen gran influencia en el control neural de la circulaci&#243;n, especialmente en situaciones envolviendo cambios significativos en la concentraci&#243;n arterial de ox&#237;geno y/o CO<sub>2</sub>. La activaci&#243;n del quimiorreflejo causa aumento de la actividad simp&#225;tica, frecuencia card&#237;aca, presi&#243;n arterial y volumen minuto. Mientras tanto, el aumento del volumen minuto y de la presi&#243;n arterial, por el <italic>feedback</italic> negativo, provoca inhibici&#243;n de la respuesta simp&#225;tica a la activaci&#243;n del quimiorreflejo. De esa forma, quimiorreflejos desencadenan diversas respuestas cardiovasculares y respiratorias, con interacciones complejas entre sus respuestas. Para definir cualquier anormalidad en la funci&#243;n quimiorreflexa es esencial considerar la contribuci&#243;n individual de cada componente que integra esa respuesta. En pacientes con IC, la estimulaci&#243;n de los quimiorreceptores centrales y perif&#233;ricos provoca aumento exagerado en la ventilaci&#243;n pulmonar y en la actividad nerviosa simp&#225;tica caracterizada por una potencializaci&#243;n selectiva de esas respuestas<sup>14,19</sup>. </p>
      <p>
        <bold>Contribuci&#243;n de los quimiorreflejos bajo condiciones de normoxia</bold>
      </p>
      <p>Los quimiorreflejos (centrales y perif&#233;ricos) ejercen un papel esencial en el control de la ventilaci&#243;n alveolar para garantizar que las tasas de intercambio gaseoso en los pulmones continuamente suplan la demanda metab&#243;lica por la captaci&#243;n de ox&#237;geno y remoci&#243;n de CO<sub>2</sub>. Frecuentemente superestimado, entre tanto, es el hecho de que esos reflejos tambi&#233;n ejercen importantes influencias en el control card&#237;aco y vascular para regular el flujo sangu&#237;neo y entonces los niveles tisulares de intercambio gaseoso. Un componente importante para activaci&#243;n del quimiorreflejo es un aumento en la actividad simp&#225;tica en los lechos vasculares. Esa respuesta ayuda a la manutenci&#243;n de la presi&#243;n arterial frente a los efectos directos vasodilatadores de la hipoxemia o hipercapnia, y entonces auxilia en la manutenci&#243;n de la presi&#243;n adecuada para el flujo sangu&#237;neo e intercambio gaseoso en los tejidos. </p>
      <p>La idea de que los quimiorreflejos contribuyen a la actividad simp&#225;tica de reposo en estados patol&#243;gicos ha sido la hip&#243;tesis que los quimiorreflejos no estar&#237;an activados en el reposo (normoxia e isocapnia) y entonces deber&#237;an tener peque&#241;a influencia en el tono simp&#225;tico bajo condiciones normales. Mientras tanto, esa hip&#243;tesis se muestra controvertida. En individuos normales en reposo, la hiperoxia, que inhibe la actividad de quimiorreceptores perif&#233;ricos, disminuye la actividad nerviosa simp&#225;tica<sup>20</sup>. Entre tanto, individuos con apnea del sue&#241;o tienen una actividad quimiorreflexa aumentada en condiciones de normoxia. As&#237;, se puede sugerir que los quimiorreflejos contribuyen para el tono simp&#225;tico aumentado en la insuficiencia card&#237;aca, aun en ausencia de hipoxia<sup>21</sup>. </p>
      <p>
        <bold>Quimiorreflejos y anormalidades ventilatorias </bold>
      </p>
      <p>La respiraci&#243;n es estimulada por los quimiorreflejos que incluyen los receptores centrales y perif&#233;ricos, el sistema nervosos central y los m&#250;sculos respiratorios. Los quimiorreflejos componen la parte de <italic>feedback</italic> negativo de un ciclo de retroalimentaci&#243;n. El ciclo es completado por la progresi&#243;n en la cual la ventilaci&#243;n alveolar controla la extracci&#243;n de O<sub>2</sub> y eliminaci&#243;n de CO<sub>2</sub>. La progresi&#243;n del ciclo relaciona la dependencia de la PCO<sub>2</sub> y de la PO<sub>2</sub> en la ventilaci&#243;n<sup>22</sup>. La estimulaci&#243;n de los quimiorreceptores resulta en una ventilaci&#243;n alveolar aumentada que lleva a una eliminaci&#243;n aumentada de CO<sub>2</sub> y ca&#237;da en la PCO<sub>2</sub>, estimulando los quimiorreceptores por medio del aumento de la concentraci&#243;n de iones H<sup>+</sup>; de esa forma, concluyendo la designaci&#243;n de retroalimentaci&#243;n negativa del sistema<sup>23</sup> (<xref ref-type="fig" rid="es_a12fig03m-body3">Figura 3</xref>). </p>
      <p content-type="asset">
        <fig id="es_a12fig03m-body3">
          <graphic xlink:href="1678-4170-abc-96-02-0161-00003-gf03-es.jpg"/></fig>
      </p>
      <p>La sensibilidad aumentada de los quimiorreflejos central y perif&#233;rico puede ejercer un importante papel en el control ventilatorio alterado en la insuficiencia card&#237;aca, siendo encontrada correlaci&#243;n significativa entre la respuesta ventilatoria al ejercicio y la quimiosensibilidad hipox&#233;mica al reposo<sup>24</sup>. La inhibici&#243;n del quimiorreflejo perif&#233;rico ha mostrado que aumenta el desempe&#241;o ante el ejercicio y disminuye la respuesta ventilatoria en pacientes con IC. Esas observaciones sugieren que la hiperpnea exacerbada ante el ejercicio puede ser influenciada por el aumento de la actividad quimiorrefleja perif&#233;rica en esos pacientes<sup>25,26</sup>. Una correlaci&#243;n positiva significativa fue encontrada entre la responsividad central ventilatoria hiperc&#225;pnica y el porcentaje del tiempo de sue&#241;o en pacientes con IC y respiraci&#243;n de Cheyne-Stokes. El hecho de que O<sub>2 </sub>y CO<sub>2</sub> suplementarios durante el sue&#241;o aumenten la respiraci&#243;n de Cheyne-Stokes sugiere una contribuci&#243;n de la quimiosensibilidad aumentada a ese desorden. Ese aumento tambi&#233;n puede explicar la tendencia de que PaCO<sub>2 </sub>menores de lo normal sea observada duranteel sue&#241;o y la vigilia en los individuos con respiraci&#243;n de Cheyne-Stokes<sup>26</sup>. </p>
      <p>En la insuficiencia card&#237;aca de etiolog&#237;a chag&#225;sica las respuestas ventilatoria y auton&#243;mica fueron aumentadas con la estimulaci&#243;n del quimiorreflejo perif&#233;rico. En contrapartida, las respuestas ventilatoria y auton&#243;mica disminuyeron durante la hipercapnia, asociada a la activaci&#243;n de los quimiorreceptores centrales en ese grupo de pacientes<sup>27,28</sup>. </p>
      <p>Adem&#225;s de eso, es importante resaltar que al lado de la enfermedad de Chagas, la diabetes es una enfermedad que puede cursar con neuropat&#237;a auton&#243;mica llevando a la disautonom&#237;a y muchas veces pacientes con IC presentan diabetes como comorbilidad. Existen pocos estudios que relacionan diabetes y la funci&#243;n quimiorreflexa. En modelos experimentales, estudios muestran que el quimiorreflejo se encuentra disminuido<sup>29</sup>. En humanos, se observa disminuci&#243;n del quimiorreflejo perif&#233;rico en individuos con diabetes tipo 2, especialmente en relaci&#243;n a la respuesta la hipoxia<sup>30</sup>. </p>
      <p>
        <bold>Influencia de la terap&#233;utica medicamentosa en los quimiorreflejos central y perif&#233;rico</bold>
      </p>
      <p>La terap&#233;utica medicamentosa es fundamental para mejor pron&#243;stico en la IC. El tratamiento contempor&#225;neo de la IC incluye betabloqueantes (BB), inhibidores de la enzima de la conversi&#243;n de la angiotensina (I-ECA) y bloqueadores del receptor de la angiotensina II (BRA). La terap&#233;utica con betabloqueantes modific&#243; de forma importante la morbilidad y mortalidad de los enfermos con IC, como fue evidenciado en los estudios COPERNICUS<sup>31</sup>, CIBIS-II<sup>32</sup> y MERIT-HF<sup>33</sup>. Los betabloqueantes disminuyen la progresi&#243;n de la disfunci&#243;n ventricular izquierda, disminuyen actividad simp&#225;tica y as&#237; mejoran el pron&#243;stico de los pacientes con IC<sup>34</sup>. Sus efectos ben&#233;ficos son evidentes independientemente de la edad o del riesgo bajo, intermedio o alto en que los pacientes se encuentran para IC<sup>35</sup>. Entre tanto eso no se traduce en mejora de la capacidad de ejercicio tanto en esfuerzo subm&#225;ximo como m&#225;ximo. </p>
      <p>Los betabloqueantes pueden actuar en los receptores beta 1 y/o beta 2 adren&#233;rgicos. El sistema respiratorio es caracterizado por prevalencia de receptores beta 2 que son caracterizados por regular el tono br&#243;nquico mientras que los receptores beta alveolares regulan la reabsorci&#243;n de fluidos que afecta la difusi&#243;n de los gases; entre tanto, m&#225;s de 90% de los receptores beta se ubican en los alv&#233;olos, en los cuales el tipo beta 2 predomina (70%)<sup>36,37</sup>. A pesar de que la terap&#233;utica con betabloqueantes es un tratamiento efectivo para la IC, hasta el presente momento, apenas algunos estudios evaluaron los efectos de betabloqueantes en la hiperventilaci&#243;n inducida por el ejercicio<sup>38</sup>. Adem&#225;s de eso, no existen datos a respecto al efecto de los betabloqueantes durante el ejercicio bajo condiciones de hipoxia, cuando la hipoxemia arterial aumenta la actividad de los quimiorreceptores<sup>39</sup>. </p>
      <p>Los inhibidores de la enzima conversora de la angiotensina (IECA) inhiben la conversi&#243;n de angiotensina I (AI) en angiotensina II (AII), disminuyendo los niveles de esta en sangre. La formaci&#243;n de la AII envuelve un clivaje secuencial del angiotensin&#243;geno. Por la acci&#243;n de la renina, sintetizada por el ri&#241;on, el angiotensin&#243;geno es desdoblado en angiotensina I, que es entonces hidrolizado en angiotensina II, por la acci&#243;n de la enzima de conversi&#243;n de la angiotensina (ECA). El sistema renina-angiotensina-aldosterona puede ser bloqueado en diferentes lugares y por mecanismos diversos. La actividad de la enzima de conversi&#243;n de angiotensina es predominantemente encontrada en el endotelio de los vasos de los pulmones. La angiotensina II promueve liberaci&#243;n de aldosterona por la suprarrenal. Los agentes que inhiben la ECA interfieren en la conversi&#243;n de la AI en AII, esta considerada una de las m&#225;s importantes hormonas sist&#233;micas, entre las cuales se incluyen noradrenalina, vasopresina y eLos bloqueadores de los receptores de la angiotensina II (BRA) son f&#225;rmacos que act&#250;an en los receptores AT1, responsables por todas las acciones conocidas de la AII, incluyendo vasoconstricci&#243;n, liberaci&#243;n de aldosterona y efectos en el miocardio y en la vasculatura (<xref ref-type="fig" rid="es_a12fig04m-body3">Figura 4</xref>). Existen hip&#243;tesis para explicar su influencia en la din&#225;mica de los quimiorreflejos central y perif&#233;ricos. A pesar de que los mecanismos celulares y moleculares envueltos en el aumento de la sensibilidad de los quimiorreceptores carot&#237;deos durante la IC aun est&#225;n poco elucidados, existen evidencias de que el aumento de la concentraci&#243;n de la angiotensina II en el sistema nervioso central acent&#250;a la sensibilidad quimiorrefleja perif&#233;rica y aumenta la actividad nerviosa simp&#225;tica perif&#233;rica<sup>40,41</sup>. </p>
      <p content-type="asset">
        <fig id="es_a12fig04m-body3">
          <graphic xlink:href="1678-4170-abc-96-02-0161-00003-gf04-es.jpg"/></fig>
      </p>
      <p>Los niveles plasm&#225;ticos y tisulares de angiotensina II est&#225;n aumentados en la IC y, adem&#225;s de eso, algunos estudios relacionan la hipersensibilidad de los quimiorreceptores en la IC al aumento en las concentraciones de AII y a la disminuci&#243;n en las concentraciones de &#243;xido n&#237;trico<sup>42,43</sup>. Estudios recientes demostraron que concentraci&#243;n end&#243;gena de AII y la expresi&#243;n de los receptores AT1 est&#225;n aumentados en los corp&#250;sculos carot&#237;deos en modelos animales de IC, y que eso media el aumento de la sensibilidad de los quimiorreceptores a la hipoxia. De esa forma, el tratamiento medicamentoso con BRA podr&#237;a afectar los quimiorreflejos en la IC, pero los estudios son, en su mayor&#237;a, experimentales en modelos animales, lo que limita la conclusi&#243;n del comportamiento de esos mecanismos en humanos<sup>41,44</sup>. </p>
      <p>
        <bold>Perspectivas</bold>
      </p>
      <p>A pesar de resultados divergentes, actualmente gran n&#250;mero de evidencias apunta para que haya un aumento en la actividad de los quimiorreflejos centrales y perif&#233;ricos en la insuficiencia card&#237;aca, lo que se correlaciona con la gravedad de la enfermedad. A pesar de que los mecanismos responsables por la sensibilidad quimiorrefleja central alterada aun sean oscuros, las alteraciones resultantes pueden ser responsables, en parte, por el aumento de la respuesta ventilatoria ante ejercicio, disnea, respiraci&#243;n de Cheyne-Stokes e hiperactivaci&#243;n simp&#225;tica observados en la insuficiencia card&#237;aca. Los f&#225;rmacos utilizados en el manejo cl&#237;nico de la insuficiencia card&#237;aca, a pesar de que disminuyen hiperestimulaci&#243;n simp&#225;tica y la sensibilidad de los quimiorreflejos central y perif&#233;rico, no mejoran el desempe&#241;o ante el ejercicio, aun amenizando s&#237;ntomas como la disnea. De esa forma, la g&#233;nesis de las se&#241;ales y s&#237;ntomas del s&#237;ndrome de la insuficiencia card&#237;aca requiere mayores esclarecimientos para que se pueda intervenir y tratar ese s&#237;ndrome de modo de mejorar pron&#243;stico, calidad de vida y desempe&#241;o ante actividades cotidianas. </p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes. </p>
      <p>
        <bold>Fuentes de Financiamiento</bold>
      </p>
      <p>El presente estudio no tuvo fuentes de financiamiento externas. </p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>No hay vinculaci&#243;n de este estudio a programas de postgrado. </p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
</article>
